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In 1990, the natural product discodermolide was isolated from a marine sponge and later found 
to have exceptional antiproliferative activity in cancer cells.  Further studies showed 
discodermolide to stabilize microtubules via the taxoid binding site on β-tubulin.  Unlike 
paclitaxel, it is not a substrate for P-glycoprotein transport, is potent in paclitaxel-resistant cell 
lines with β-tubulin mutations, exhibits better water solubility, and can act synergistically when 
combined with paclitaxel treatment.  For this reason, discodermolide has been the focus of many 
synthetic and biological studies, culminating in a 60 gram-scale synthesis and Phase I/II clinical 
trials carried out by Novartis in 2004.  Despite the great level of interest from the scientific 
community, much about this compound’s behavior in vivo is still unknown.  An extended 
analysis of known structure-activity relationships for discodermolide is presented herein.  Also 
reported are the syntheses of a series of discodermolide fragments, which are designed to enable 
the formation of a novel analogue library via late-stage multicomponent reactions.  Fragments to 
be synthesized prior to coupling are streamlined alternatives to the discodermolide framework 
that have shown promise in prior analogue and HQSAR studies. Overall, these modifications 
have been designed to improve the efficiency of synthetic efforts and to represent a wholly 
unique series of analogues for biological study. 
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 1.0  INTRODUCTION 
Marine life has long been established as a leading source of a diverse and potent array of potent 
biologically active natural products.1  Consequently, marine bioprospecting has yielded 
numerous promising targets for future biomedical research and application.  One of these 
compounds, (+)-discodermolide (Figure 1) was first isolated from the marine sponge 
Discodermia dissoluta in 1990 by the Harbor Branch Institution, Inc. and shown to have 
immunosuppressive activity.2–5  Later studies established discodermolide as an extraordinarily 
potent microtubule (MT) stabilizer.  MTs are essential and dynamic cellular structures, involved 
in multiple critical functions including signaling, intracellular transport, and division.  Because 
cancer cells often rely heavily on these mechanisms for growth and proliferation, MTs and their 
tubulin subunits are viable targets for cancer therapeutics.6  With potency rivaling that of the 
industry standard of the time, paclitaxel, discodermolide garnered significant interest in the 
scientific community.  
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Figure 1. The structure of (+)-discodermolide and other microtubule-stabilizing agents. 
 
Several total syntheses were completed in succeeding years to circumvent natural supply 
limitations and allow for more thorough biological studies.7,8  It was found that discodermolide 
acted as a MT-stabilizing agent with impressive potency, drawing comparisons to paclitaxel and 
the more recently established epothilone series (Figure 1).9  Altogether, discodermolide contains 
13 stereogenic centers, a tetrasubstituted δ-lactone, a di-substituted and tri-substituted (Z)-olefin, 
a terminal (Z)-olefin, and a carbamate moiety.  This complex functionalization made total 
synthesis efforts challenging.  Overcoming this challenge, efforts towards total synthesis of the 
compound culminated in the production of over 60 g of the natural product by Novartis for 
preliminary clinical trials.  In 2004, these initial Phase I/II trails were halted due to pneumotoxic 
effects experienced by 3 patients in the course of the study, possibly due to metabolite 
formation.10,11  
Herein are reported efforts towards the design and synthesis of simplified analogues of 
discodermolide for biological evaluation.  Total syntheses attempts in the past have yielded gram 
quantities of the compound, but have also highlighted the difficulties inherent in the synthesis of 
such a complex polyketide.  By simplifying the structure of discodermolide, it is hypothesized 
that a more facile synthesis can be obtained without significantly sacrificing MT stabilizing 
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 activity.  A multicomponent reaction (MCR) approach will be carried out for late-stage coupling 
of analogue fragments that will increase the potential for structural diversity and enable a more 
complete structure-activity relationship (SAR) profile to be developed for this promising drug 
target. 
1.1 TARGETING MICROTUBULES IN THE TREATMENT OF CANCER 
The cytoskeleton of eukaryotic cells is composed of three distinct types of structural proteins: 
microtubules, microfilaments such as actin, and intermediate filaments.6  Diverse cellular 
functions of MTs include key roles in structural support, mitosis, meiosis, motility, and the 
transport of macromolecules.  They are a polymeric species comprised of alpha and beta tubulin 
heterodimers, which are in a constant state of dynamic instability. The polymerization and 
organization of the MT strands differ by the needs of the individual cell, which are determined 
by location, type, and phase in the cell cycle. 
Generally, eukaryotic MT spindles contain 12-13 linear chains of tubulin heterodimers 
called protofilaments (Figure 2a).12  Protofilaments nucleate and are then held together through 
lateral bonds to form a hollow cylinder about 25 nm in diameter. The heterodimer subunits 
within each protofilament have the same orientation, so at one end (designated as minus), α-
tubulin is exposed and at the opposite end (designated as plus), β-tubulin is exposed (Figure 
2b).12  GTP attached to the β-tubulin at the exchangeable nucleotide site (E-site) provides 
requisite energy for assembly and disassembly.  Once a heterodimer is incorporated into the 
growing MT, this β-tubulin GTP is hydrolyzed to GDP after a brief delay by the β-tubulin.  
Exposure of GDP-tubulin at the + end of the tubulin strand leads to the rapid dissociation of the 
 3 
 heterodimers, a process designated as catastrophe (Figure 2c).12  MT dynamics are characterized 
by abrupt and asynchronous periods of catastrophe and recovery, allowing them to act as rigid 
structural support while simultaneously being capable of sudden depolymerization.  
 
 
Figure 2. The structure of the microtubule and its tubulin subunits.   
a) The MT protofilament is composed of repeating αβ-tubulin dimers; b) Parallel protofilaments align to form the 
hollow MT; c) the process of MT growth and catastrophe, via hydrolysis of GTP. Reprinted with permission from 
Macmillan Publishers Ltd: Ref. 12, copyright 2008.  
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 Notably, MTs are responsible for the quick reorganization of replicated chromosomes 
during mitosis. The lengthy interphase MT strands disassemble at the onset of mitosis and 
become 4-100 times more dynamic, exhibiting half-times of 10-30 sec.13–15  After the breakdown 
of the nuclear envelope, MTs probe the cytoplasm for chromosomes and converge at the spindle 
poles once the MT is attached to the chromosomal kinetochore.  Finally, duplicated 
chromosomes separate and move towards the cell periphery as the daughter cells divide.  
Deviation from this carefully regulated process often results in cell cycle arrest in a 
prometaphase/metaphase-like state that leads to apoptosis. 
Mitotic inhibition has proven itself to be a powerful tool for cancer treatment.  Because 
MT dynamics are so critical for proper cell division, interruption of this process through 
stabilization or destabilization of the polymers can have a dramatic effect on cell populations.16  
Many types of cancer cells divide more frequently than healthy cells, and therefore have a 
substantial vulnerability to this type of interruption.  The mechanisms of specific anti-mitotic 
agents on MT polymerization vary, but they are generally designated as either MT-stabilizing or 
MT-destabilizing agents.  Depending on the individual drug’s mechanism of action, it may bind 
to the MT directly and/or to soluble tubulin.  An additional point of difference between anti-
mitotic drugs may be their binding site along the MT framework.   
A good example of the general diversity of these drugs lies in a comparison of the 
popular drugs vinblastine and paclitaxel.  Vinblastine binds to β-tubulin at the “plus” end of the 
MT, causing the protofilaments to begin curling and suppressing further polymerization.17–19  
MT dynamics are slowed dramatically, and mitosis stalls with chromosomes unable to segregate 
at  the spindle poles.  The dramatic influence of vinblastine on the MT network can be seen in 
 5 
 Figure 3.20  As more drug is added, cells experience difficulties with chromosomal separation 
and appear misshapen and multinucleated, reentering G1 phase without dividing.   
 
 
Figure 3. Immunofluorescence assay showing the effects of vinblastine on CHO cells. 
Cells were treated 2 days with the indicated concentration of vinblastine, and then stained with DM1A for tubulin 
(green) and DAPI for DNA (red).  Upper inserts show representative mitotic cells.  Adapted with permission from 
the American Society for Biochemistry and Molecular Biology, Ref. 20, copyright 2010.  
 
In contrast to the behavior of vinblastine, paclitaxel is known as an MT stabilizer.  It 
preferentially binds to the inner surface of the β-tubulin with a 1:1 stoichiometry when at high 
concentrations of paclitaxel (Figure 4, left).21,22  Even though the typical MT contains 10,000 
tubulin subunits, just one molecule of paclitaxel per several hundred tubulin subunits is required 
to reduce MT shortening by about 50%.23  Interaction with paclitaxel stabilizes the MT polymer, 
interrupting mitosis by forming MT bundles during interphase and preventing spindle asters from 
disassembling (Figure 4, right).24  Despite its promising activity, the low aqueous solubility and 
development of cancer cell resistance to paclitaxel – typically through overexpression of P-
glycoprotein (Pgp) or β-tubulin mutations – leaves much room for improvement for this type of 
therapeutic agent. 
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Figure 4. The binding of paclitaxel to β-tubulin (left) increases MT stability and bundling (right). 
Left: Paclitaxel in the β-tubulin binding site of the tubulin heterodimer. Right: HeLa cells were incubated for 14.5 h 
in the presence of either drug vehicle (A and C) or 1 μM paclitaxel (B and D).  Images depict either labeled nuclei 
(A and B) or immunolocalized tubulin (C and D).  Arrows identify subpopulations experiencing different stages of 
mitosis when treated with drug vehicle (A and C) or those with MT bundling when treated with drug (B and C). 
Image at left reprinted with permission from Cell Press, Ref. 22, copyright 2009; image at right reprinted with 
permission from The American Association for Cancer Research, Ref. 24, copyright 2002.  
 
1.2 BIOLOGICAL ACTIVITY OF DISCODERMOLIDE 
1.2.1 Immunosuppressive Activity 
Shortly after its isolation in 1990, scientists at the Harbor Branch Oceanographic Institute, Inc. 
found discodermolide to exhibit immunosuppressive activity in murine in vitro and in vivo graft 
versus host splenomegaly studies.3–5  Its activity was comparable to that of cyclosporine A, and 
in these studies activity was attributed to a general antiproliferative effect on lymphoid cells at 
low nM concentrations.  Cell cycle studies showed that treatment with discodermolide resulted in 
reversible G2/M cell cycle arrest.5  At the same time, Gunesekera and co-workers at Harbor 
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 Branch elucidated the structure and relative stereochemistry of the compound through an array of 
1- and 2-dimensional NMR experiments, as well as X-ray crystallography.2 
1.2.2 Antiproliferative Properties Due to Microtubule Stabilization 
By 1996, a collaboration between Day and ter Haar demonstrated that the observed cell cycle 
arrest of discodermolide-treated cells was related to MT binding and stabilization.8  In their 
seminal study, it was shown that the MTs of MCF-7 cells exhibited significant morphological 
changes in the presence of discodermolide.  The IC50 after 48 h of continuous drug exposure was 
found to be 2.4 nM, whereas that for the benchmark MT stabilizer paclitaxel was 2.1 nM.  The 
cytotoxicity of paclitaxel and discodermolide were found to be quite similar, although further 
comparison to paclitaxel with in vitro models revealed several notable differences between the 
two.  Discodermolide prompted a more rapid and significant bundling of the MT network when 
compared to paclitaxel, as shown in Figure 5.25 
 
  
Figure 5. Cancer cells (left) treated with discodermolide (right) display MT bundling and hypernucleation. 
 Immunofluorescence staining shows the reorganization of cellular DNA (red) and tubulin (green) within the cells.  
Reprinted with permission from Ref. 25, Florida Atlantic University, Harbor Branch Oceanographic Institute.  
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 Turbidity studies with purified tubulin demonstrated the superior ability of 
discodermolide to promote the hypernucleation of tubulin assembly in conditions that typically 
favor depolymerization.  An experiment highlighting this phenomenon is depicted in Figure 6, 
where tubulin polymerization was monitored in the absence of drug (curve 1), with 10 µM 
paclitaxel (curve 2), or with 10 µM discodermolide (curve 3).  Here, a higher level of absorbance 
correlates to an increase in turbidity brought about by tubulin assembly. 
 
 
Figure 6. Stimulation of MT assembly by discodermolide and paclitaxel.   
Reaction mixtures contained 0.1 M Mes buffer, 4% DMSO, 10 μM tubulin, 100 μM GTP, 5 μM heat-treated MAP.  
Reprinted with permission from Ref. 8, copyright 1996 American Chemical Society. 
 
A separate series of experiments in the same study showed that discodermolide polymers 
persisted even with minimal concentrations of drug and in conditions typically favoring 
depolymerization.  These conditions included low temperatures, addition of up to 5 mM of 
catastrophe-promoting Ca2+ salts, and the omission of stabilizing microtubule-associated proteins 
(MAPs).  Additionally, the number and length of tubulin polymers produced was quantified 
through electron microscopy studies.  MT length in discodermolide-treated cells was proven to 
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 be independent of temperature, with 0.5-0.6 μm average lengths at temperatures between 0oC 
and 37oC.  Paclitaxel was unable to hypernucleate tubulin assembly as significantly, and 
polymers averaged over 1.6 μm in length in the same conditions.  These exciting results 
demonstrated the potential for discodermolide as a novel therapeutic agent in neoplastic disease.   
  Concurrent to this work, the Schreiber group carried out studies to determine the 
specific binding affinities of discodermolide compared to paclitaxel.26  A series of experiments 
exposing tubulin to radiolabelled [3H]-paclitaxel and then [3H]-discodermolide enabled the group 
to perform competitive binding studies.  They found that discodermolide treatment initiated cell 
cycle arrest in the metaphase-anaphase transition in mitosis by binding to tubulin dimers with a 
1:1 stoichiometry.  In a final experiment, a solution containing 10 µM of purified tubulin dimers 
were exposed to an equal concentration of [3H]-paclitaxel or [3H]-discodermolide and allowed to 
undergo polymerization until saturated.  Increasing amounts of unlabeled discodermolide or 
paclitaxel, respectively, were added as competitors for each system.  They found that while 
unlabeled discodermolide was able to effectively displace [3H]-paclitaxel, unlabeled paclitaxel 
was unable to do the same with [3H]-discodermolide.  Even at concentrations of up to 50 μM 
unlabeled paclitaxel, discodermolide was not displaced.  The results clearly demonstrated the 
higher affinity of discodermolide compared to paclitaxel.  The two compounds bound to 
mutually exclusive locations on tubulin, but it was uncertain whether they bound to the protein at 
the same or overlapping sites, or whether binding induced a conformational change that made 
simultaneous association impossible. 
Amidst growing interest in discodermolide, the compound was assayed against colon and 
ovarian carcinoma multi-drug-resistant (MDR) cell lines (SW620AD-300, A2780AD) and cell 
lines that exhibit β-tubulin mutations (1A9PTX10, 1A9PTX22).9  All four of these cell lines 
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 were known to be paclitaxel-resistant, so this provided a further opportunity to explore potential 
differences in activity between the compounds. The IC50 values of the drug-resistant cell lines 
were compared to the parent drug-sensitive cell line in order to quantify the degree to which 
potency was diminished between the two.  In all cell lines studied, discodermolide was 
significantly more potent than paclitaxel.  Interestingly, further studies of cells containing β-
tubulin mutations revealed that discodermolide did not exhibit cross-resistance in epothilone- 
and paclitaxel-resistant cell lines.  An impressive example was that the potency of paclitaxel was 
diminished 930-fold in SW620AD-300 cells whereas similar treatment with discodermolide 
resulted in only 25-fold drop in potency.  Similarly, discodermolide retained its full potency in 
the drug-resistant 1A9 lines but paclitaxel was 23- and 29-fold less potent.  A major contributing 
factor for this is hypothesized to be discodermolide’s minimal affinity for Pgp and lesser 
sensitivity to βI-tubulin isotype mutations.9,27 
In the past decade, there have been several notable studies to elucidate the mechanism of 
action for discodermolide.  In 2003, Jordan and colleagues investigated MT dynamics and 
determined them to be altered in a concentration-dependent manner.28  Dynamicity, which is the 
total length grown and shortened divided by the lifespan of the MT population, was used as a 
measure to reflect overall exchange of tubulin.  At 7 nM in A549 cells, the measure of 
dynamicity (an IC50 value for proliferation) was reduced by 23%.  At the value for 50% maximal 
mitotic block (83 nM), most MTs were non-dynamic, no cells arrived at anaphase, all spindles 
were abnormal, and 62% reduction of dynamicity was observed.  This suggests that reduction of 
dynamicity of MTs is an essential mechanism for inhibiting proliferation.29 The group postulated 
that reduced MT lengths limited the ability of the strands to probe the cytoplasm for 
chromosomal kinetochores during pro-metaphase and for chromosomal separation in anaphase. 
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 In 2009, Horwitz and colleagues elaborated upon the MT stabilization studies using 
hydrogen-deuterium exchange (HDX) studies in the presence of GTP and free tubulin.22  This 
type of experiment identifies specific residues on the tubulin binding site that are protected from 
deuterium incorporation after ligand association.  Paclitaxel was shown to stabilize 
interprotofilament binding through contacts with the β-tubulin M-loop, as well as reducing 
deuterium incorporation on the β-face of the interdimer region (Figure 7).  In contrast, 
discodermolide stabilized the interprotofiliment region at the β-tubulin H1-S2 loop and protected 
the interdimer region more strongly on the α-face.  In this way, the binding of discodermolide 
appears be complementary to that of paclitaxel.  Unique to discodermolide was additional 
protection in the exchangeable nucleotide binding site (E-site) that is responsible for stabilization 
of GTP binding, and in the region on α-tubulin containing Glu254, which is involved in GTP 
hydrolysis.  This suggests discodermolide may have a more extensive ability to hinder GTP 
hydrolysis, the primary cause of catastrophe. 
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Figure 7. Differences in tubulin binding contacts between paclitaxel and discodermolide. 
Paclitaxel is shown in the binding site on the tubulin dimer.  Binding contacts unique to paclitaxel or discodermolide 
are shaded (red and yellow, respectively) and shared contacts are shown in orange.  Also included are structures of 
GDP and GTP in their respective binding sites (dark green), and cartoon representations of the M-loop (red) and H1-
S2 loop (blue) within β-tubulin.  Three-dimensional structural data and protein sequence were obtained from the 
Protein Data Bank (PDB) ID: 1JFF and MacPyMOL was used to render and visualize the structure.  The author used 
data from Horwitz’s HDX studies to assign binding contacts for both discodermolide and paclitaxel.   
 
Using an integrated NMR spectroscopy and computational approach, the binding 
mechanism of MT stabilizing agents (MSAs) was further explored by Díaz and colleagues in 
2011.30  MSAs were detected interacting with unpolymerized tubulin heterodimers, suggesting 
that the compounds may help to promote polymerization of dimers in addition to stabilizing the 
polymerized MT structure.  Further saturation transfer difference NMR (STD) and TR-NOESY 
experiments allowed researchers to elaborate on a 2-step mechanism for binding.31  It was known 
at the time that paclitaxel and its biomimetics were able to bind to one or two internal (luminal) 
sites in addition to an external pore site.  Because of the 1:1 binding stoichiometry for 
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 discodermolide to tubulin, these sites must be mutually exclusive, but may occur in sequence.31–
33  First, the group found that the MSAs studied bind to an external site on the tubulin and 
quickly dissociate, internalizing themselves toward a secondary luminal binding site.  
Dissociation of the MSA from the tubulin occurs in a reverse process, in which the MSA slowly 
dissociates from the luminal site and is transported to an external pore site, followed by rapid 
release of the ligand from the pore.  It had been previously shown that this process occurs within 
2 minutes and that the rate-determining step was the first slow step of dissociation.34  Because 
both NMR techniques rely on rapid dissociation that fit within the relaxation time scale, it was 
expected that the very high-affinity binding of MSAs to the luminal site would be NMR-silent.  
The result of this study corroborated what had already been predicted for the MSA-tubulin 
system.  Even with this data, however, there is still some ambiguity about the precise binding 
sites of the individual compounds studied. 
1.2.3 Discodermolide’s synergism with Paclitaxel 
Drugs that behave synergistically show great promise in the realm of chemotherapeutics.  The 
enhanced potency of the drugs when given in combination allows for lower dosing of each drug, 
reduced likelihood of resistance mechanisms, less severe negative side effects, and potential for 
non-overlapping toxicity profiles.35  Despite the noted differences in the behavior of paclitaxel- 
and discodermolide-treated cells, it was still surprising when researchers found that they 
represent a synergistic drug combination for the treatment of cancer.   
In 2000, it was first found that the treatment of four separate human carcinoma cell lines 
with both drugs resulted in a schedule-independent synergistic interaction.27  The group began 
their study using A549-T12 cells, which are known to be 9-fold resistant to paclitaxel, but also 
 14 
 dependent on low levels of it (2-6 nM) for growth.  Discodermolide was distinguished from 
epothilones A/B (Figure 1) and eleutherobin early in the study when it was shown to be an 
insufficient substitute for paclitaxel in this cell line.  This has since been confirmed in other 
experiments with cell lines that have similar dependencies.36  Surprisingly, discodermolide was 
then found to be significantly more potent in the presence of paclitaxel in all four other cell lines, 
while the potency of the epothilones and eleutherobin was unaffected (Figure 8).  Synergism has 
been observed with combinations of MT-perturbing agents, although in these cases the agents 
had either independent mechanisms of action or binding sites.37–43  This was unexpected for two 
drugs with a similar apparent binding site and mode of action; it was expected that the 
combination would be either additive or antagonistic. 
 
  
Figure 8. Synergistic effects of A549 cell treatment with discodermolide and paclitaxel. 
Left: Percentage changes in the parameters of dynamic instability that were altered by treatment of A549 cells by 7 
nM discodermolide and 2 nM paclitaxel.  GR, growth rate; SR, shortening rate; LBRF, length-based rescue 
frequency; TBCF, time-based catastrophe frequency; LBCF, length-based catastrophe frequency; OD, overall 
dynamicity. Right: Mean combination index values as a function of cells killed, calculated after treating A549 cells 
with a drug combination of equipotent molar ratios (1:20 paclitaxel:discodermolide) for 72 h.  FA, fraction affected, 
synergism at CI < 1, additivity at CI = 1, antagonism at CI > 1.  Image at left reprinted with permission from Ref. 44, 
copyright 2004, American Chemical Society; image at right reprinted with permission from Ref. 45, copyright 2006, 
American Chemical Society. 
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 A follow-up study by Jordan and co-workers in 2004 further investigated the synergism 
of the two drugs with relation to their effects on MT dynamic instability.44  When tested 
separately at their IC50 values (7 nM discodermolide, 2 nM paclitaxel), dynamic instability 
parameters for the A549 cells appeared qualitatively and quantitatively similar.  However, at 
concentrations inducing 80% maximal G2-M arrest (IC80: 83 nM for discodermolide, 6 nM 
paclitaxel), they noted that discodermolide had no effect on length-based catastrophe frequency 
whereas it was increased by 80% for paclitaxel.  This suggests that paclitaxel selectively 
stabilizes the center of the MT while allowing the ends to experience frequent brief catastrophes 
and rescues.  When cells were treated with both compounds, synergism could be observed in 
various measures of dynamicity (Figure 8A).46  While the mechanism for discodermolide 
binding was still unknown, they postulated that synergism could be the result of: occupancy on 
multiple sites of a single MT, cooperative binding of paclitaxel that enhances that of 
discodermolide, preferential binding to differing tubulin isotypes, conformational changes that 
influence cellular regulators of MT dynamics, or an additional antiproliferative mechanism that 
was at that time unknown.  
In addition to cell cultures, the synergistic phenomena has also been observed in an 
ovarian xenograft tumor model in nude mice.35  Tumor volume, xenograft vascularization, and 
angiogenic effects were all assessed.  This study validated previous in vitro studies, clearly 
showing that combination therapy in this case was highly effective at low concentrations (< 20 
nM) and significantly superior to treatment with one drug alone.  While suppression of cell 
proliferation was identified as the primary mode of cell death, other contributing factors were 
also presented including: cell senescence, caspase activation, differences in affinity across 
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 tubulin isotypes, and antiangiogenic effects.  Pleasingly, due to the low dosage, no side effects 
such as toxicities or weight loss were observed.   
1.2.4 Accelerated Cell Senescence and Resistance Mechanisms 
A 2005 collaborative study between Horwitz and Smith demonstrated that in addition to mitotic 
aberrations, discodermolide treatment led to accelerated cell senescence (ACS) in multiple cell 
lines.47  ACS occurs when tumor cells initiate proliferation arrest as a response to cellular stress 
such as chemotherapeutic treatment.48,49  Biomarkers for these cells include a flattened 
morphology and elevated levels of senescence-associated β-galactosidase (SA-β-gal) activity.50   
Interestingly, treatment with paclitaxel resulted in mitotic arrest, but little or no observed 
senescence.  In fact, the researchers noted that the effects of discodermolide more closely 
resembled that of doxorubicin, a DNA-damaging drug.  This was the first time that a MT-
stabilizing drug had ever been observed using accelerated senescence as a means of suppressing 
tumor cell growth. 
It was hypothesized that paclitaxel and discodermolide, though both MT-stabilizing 
drugs, had unique and disparate effects on the MAPK signaling pathway that is involved in 
mitogenic activation.47  This finding may explain apparent pharmacokinetic differences between 
the two drugs.51  For instance, discodermolide has a higher affinity for and ability to nucleate 
MTs, but generally exhibits a lower overall cytotoxicity than paclitaxel.  Additionally, 
discodermolide does not always appear resistant in cell lines containing β-tubulin mutations or 
elevated Pgp levels that affect paclitaxel and the epothilones.  Finally, inhibition of cell 
proliferation required seven times the concentration of discodermolide compared to paclitaxel 
over a short time period (3 days), but over a longer period (6 days), equal concentrations of drug 
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 resulted in equivalent levels of apoptosis.  This delayed response exhibited by discodermolide-
treated cells may be explained though an alternate mechanism where abnormal cells are allowed 
to continue dividing until cellular stress levels bring about senescence.  It is also possible that 
discodermolide has one or more other targets in addition to the MTs, which would help to 
explain the synergism observed between the two drugs.   
Later investigations identified 4E-BP1 mRNA as a regulator of ACS initiated by 
discodermolide treatment.49  In fact, discodermolide was shown to be seven-fold resistant to 
AD32 cells, which underexpress 4E-BP1 and therefore escape ACS.  Differing resistance 
mechanisms between discodermolide and other MT stabilizing agents offer additional motivation 
for discodermolide development.  While a patient who has been previously treated with taxane-
based chemotherapeutics may experience future resistance to both taxanes and epothilones, the 
β-tubulin and/or Pgp mutations of their cells should not mitigate the efficacy of discodermolide 
treatment.36  These findings are all very exciting, but raise many questions regarding the 
relationship between ACS and tumor cell proliferation. 
1.3 PREVIOUS TOTAL SYNTHESES OF DISCODERMOLIDE 
Despite initial interest in discodermolide, the extremely low abundance (0.002 wt%) of the 
compound obtained from marine sponge samples made further studies impractical.  Unable to 
develop a robust fermentation process to alleviate the supply shortages, scientists turned to total 
synthesis.  The densely functionalized nature of discodermolide also created additional 
challenges. 
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 The first total synthesis of the unnatural (–)-discodermolide was completed by the 
Schreiber group in 1993.52  A year later, its natural antipode, (+)-discodermolide (1), was 
obtained by the group.53   The early work of Schreiber was particularly significant in that it led to 
the unambiguous assignment of absolute stereochemistry, the first SAR studies of the compound, 
and culminated in the realization of distinct roles of natural and unnatural discodermolide in cell 
cycle arrest.7 
Over subsequent years, several other groups completed total syntheses of discodermolide.  
Notably, in 1995, the Smith group took advantage of the repeating 1,2-anti-2,3-syn stereotriad 
found in three key subunits of the backbone: at C1-C8, C9-C14, and C15-C21 (Figure 9).54  By 
synthesizing a common precursor for these three subunits, a more convergent approach was 
possible.  Additionally, the synthesis of this precursor could be executed on up to a 50 g scale, so 
large quantities of each fragment could be obtained prior to coupling.  Later strategies by Smith 
and many other groups similarly used a common precursor approach such as this one.55,56  To 
date, there have been 13 unique total syntheses of discodermolide, which are summarized in 
Figure 9 below.7,52–54,57–76  From these, three representative syntheses are highlighted below: the 
fourth-generation synthesis by the Smith group, the third generation synthesis by the Paterson 
group, and the Novartis 60 g scale synthesis. 
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Figure 9. A summary of completed total syntheses of discodermolide, 1993-2007. 
 
1.3.1 The Smith Group Fourth-Generation Synthesis 
The fourth-generation synthesis developed by the Smith group in 2005 highlights the variety of 
improvements that were made over the course of a decade, making the overall strategy more 
convergent and more amenable to scaling up.77  Smith’s ultimate goal was the development of a 
scheme that would permit larger-scale production of the compound, making it more viable for 
clinical development.  Earlier schemes suffered from a variety of problems that reduced their 
practicality on a large scale, including a key Wittig coupling that required ultra-high-pressure 
conditions and led to a variety of undesired side products.59  Building on the success of their 
gram-scale synthesis, the group maintained a convergent approach that involved the formation of 
three advanced intermediates from a common precursor (6) containing the requisite stereotriad 
(Scheme 1).69 
Research 
Group Year 
Steps in the 
Longest Linear 
Sequence 
Overall 
Yield (%)a Ref. 
Schreiber   1993 24 4.3 52b,7,53 
Smith (I) 1995 28 2.2 54b 
Myles 1997 22 1.1 57b 
Marshall 1998 29 2.2 58 
Smith (II) 1999 24 6.0 59 
Paterson (I) 2000 27 7.7 60 
Paterson (II) 2003 24 5.1 74 
Smith (III) 2003 24 1.9 70 
*  Novartis 2004 26 1.1 61–65 
*  Paterson (III) 2004 21 11.1 75,76 
Panek 2005 27 2.1 67 
*  Smith (IV) 2005 17 9.0 68 
Ardisson 2007 21 1.6 73,137 
a Overall yield as reported by the author(s). 
b Synthesis of the unnatural antipode, (–)-discodermolide. 
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Scheme 1. Smith’s fourth-generation retrosynthetic plan, with stereotriad locations labeled. 
 
Although construction of 2 could be accomplished from 6, a shorter route from Roche’s ester 3 
was used instead (Scheme 2).  A sequence of steps including protection, reduction, oxidation, 
and Evans aldol reaction with chiral auxiliary afforded 7, which established the stereocenters at 
C17-C18.  Further protection, reductive removal of the auxiliary, and Parikh-Doering oxidation 
to the aldehyde led to 8.  Subsequent Brown crotylation led to the formation of the final two 
stereocenters, at C19-C20.  Protection of the secondary alcohol and ozonolysis of the terminal 
olefin provided aldehyde 9.  Finally, the completed fragment 2 could be obtained under 
Yamamoto’s conditions followed by trityl deprotection and iodination.78  This sequence required 
a total of 13 linear steps, and provided 2 in 19% overall yield. 
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Scheme 2. Smith’s fourth-generation synthesis of fragment 2. 
 
The synthesis of the other two fragments relied on the common precursor 6, which was 
developed in the first-generation scheme for the group (Scheme 3).54  This efficient 5-step 
process relied on a succession of protection, reduction, and oxidation steps leading to 
intermediate 11.  From here, Evans syn-aldol addition of 11, followed by Weinreb 
transamidation, yielded the common precursor.  This route was highly scalable, allowing for up 
to 50 g quantities of 6 to be synthesized at a time. 
 
 
Scheme 3. Smith’s fourth-generation synthesis of common precursor 6. 
 
The lactone fragment was constructed from a scheme that was modified from the group’s first-
generation synthesis as well (Scheme 4).  From the common precursor (6), protection with TBS 
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 was followed by deprotection of the terminal alcohol and subsequent oxidation to the aldehyde.  
A chelation-controlled Mukaiyama aldol reaction established the configuration at C5 by using 
TiCl4 as an external asymmetric promoter.79 The eight-membered ring chelate (12) ensured the 
desired formation of the anti-Felkin addition product 14 (via 13). Treatment with acid afforded 
the ring-closed 15, whose enone could then undergo directed reduction to form an allylic alcohol.  
From there, protection and ozonolysis furnished the completed lactone fragment 5. 
 
 
Scheme 4. Smith’s fourth-generation synthesis of lactone intermediate 5.  
 
From the common precursor, synthesis of what would become the linker fragment, 4, required 
only six additional steps (Scheme 5).  Protection of the secondary alcohol followed by reduction 
of the amide allowed for the installation of the requisite trisubstituted vinyl iodide 16.  The 
conversion of 16 to Wittig salt 4 represented an improvement from earlier syntheses, which 
relied on high pressure conditions or led to undesirable cyclopentane-containing side products.  
This bifunctional intermediate also allowed for the direct sequential coupling to both carbamate 
and lactone fragments. 
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Scheme 5. Smith’s fourth-generation synthesis of linker fragment 4. 
 
Coupling of the linker fragment 4 with the lactone 5 through the Wittig salt yielded vinyl iodide 
17, which could then be used in a Suzuki coupling reaction with diene 2 (Scheme 6).  With the 
completed discodermolide backbone in place, only deprotection and installation of the carbamate 
was needed to furnish 1.  This process required only 17 linear steps, with a 9.0% overall yield.   
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Scheme 6. Smith’s fourth-generation coupling of advanced intermediates to form 1. 
 
1.3.2 The Paterson Group Third-Generation Synthesis 
The Paterson group reported their first total synthesis of discodermolide in 2000, five years after 
the Smith group’s initial attempt.60 Their early approach was also convergent, and relied on a 
novel boron-mediated aldol coupling to independently construct three advanced intermediates.  
Four years later, the group presented a third-generation approach that improved the overall 
convergence and streamlined the synthesis so it would be more amenable to an industrial scale.75  
The group envisioned a late stage Still-Gennari-type HWE olefination to join β-ketophosphonate 
19 and aldehyde 21, as can be seen in Scheme 7. 
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Scheme 7. Paterson’s third-generation retrosynthetic plan. 
 
The synthesis of β-ketophosphonate 19 began with installation of the stereotriad through a 
borane-mediated anti-aldol addition (Scheme 8).  Here, the (E)-enol dicyclohexylborinate 
formed, allowing an aldol reaction via the chair-like transition state 24. Reduction in situ of the 
resulting boron aldolate resulted in axial hydride delivery through transition state 25, which 
minimizes steric interactions between cyclohexyl ligands and the benzyl ether group.80  
Conversion of syn-diol 26 to an acetal was followed by PMB deprotection, oxidation of the 
newly-formed primary alcohol, and methylation to 27.  In order to install the requisite 
phosphonate scaffold, the benzyl ether was removed through hydrogenolysis, and then oxidized.  
Finally, treatment of acid 28 with the Ghosez reagent generated the acid chloride, which was 
then converted to the desired phosphonate 19 through an acylation reaction. 
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Scheme 8. Paterson’s third-generation synthesis of β-ketophosphonate 19.   
L = c-Hex, R1 = CH2OPMB, R2 = CH2CH2OBn. 
 
Beginning from ethyl ketone 20, intermediate 23 could be constructed in 11 steps (Scheme 9).  
Formation of the (E)-boron enolate of 20 and subsequent anti-selective aldol reaction established 
the stereochemistry of the methyl group at C18.  β-Hydroxy-directed reduction of the ketone 
moiety produced a diol, whose terminal ether underwent methanolysis to provide a terminal 
alcohol.  Glycol cleavage to form aldehyde 29 was followed by reduction, TBS protection of the 
primary alcohol, and DDQ-mediated acetal formation.  Regioselective opening of the acetal 
effectively shifted the PMB group to the secondary alcohol, allowing the oxidation of the newly-
deprotected terminal alcohol.  Installation of the (Z)-diene occurred in a three-step process 
involving Nozaki-Hiyama-Kishi allylation to form the anti-β-hydroxysilane 32, then 1,2-syn-
elimination, and finally oxidation to generate the desired aldehyde 23. 
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Scheme 9. Paterson’s third-generation synthesis of aldehyde intermediate 23. 
 
 
Beginning from advanced intermediate 29, a Still-Gennari HWE reaction yielded an enoate 
containing the desired internal (Z)-olefin (Scheme 10).  Protection of the secondary alcohol and 
reduction of the ester produced 34, which underwent homologation to the iodide.  Finally, 
alkylation with the lithium enolate shown below produced aryl ester 22. 
 
 
Scheme 10. Paterson’s third-generation synthesis of aryl ester 22. 
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 Coupling of intermediates 22 and 23 began with enolization of the aryl ester moiety of 22 
generated an (E)-lithium enolate, which then formed the desired 1,2-anti aldol adduct in the 
presence of 23 (Scheme 11).  In order to transform the aryl ester at C16 into the desired methyl 
group, lithium aldolate 35 was subjected to an in situ reduction, sulfonation and subsequent 
deoxygenation.  Protection of the secondary alcohol at C17 yielded 36, then selective 
deprotection and oxidation of the primary alcohol gave a product that was ready for the final 
coupling stages.  A Still-Gennari HWE reaction with phosphonate 19 produced the desired olefin 
with 10:1 Z:E selectivity.  With the complete backbone of discodermolide in place, the group had 
only to carry out a final series of functional group manipulations.  Thus, discodermolide was 
synthesized after deprotection, carbamate formation, 1,2-reduction at C7, and lactone cyclization 
steps. 
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Scheme 11. Endgame coupling strategy of Peterson’s third-generation synthesis. 
 
Overall, Paterson’s third-generation synthesis of discodermolide relied on much of the chemistry 
previously developed within the group, like the preference for substrate-controlled over 
auxiliary-controlled reactions in order to achieve stereocontrol.  The most notable modification 
was the relatively mild late-stage Still-Gennari-type HWE olefination.  These improvements 
allowed for a milder endgame strategy, less reliance on boron-mediated aldol reactions, and 
minimized expense for scaled-up syntheses. 
1.3.3 The Novartis 60-g Scale Synthesis 
Due to the great promise of discodermolide as a novel chemotherapeutic agent, a practical 
synthesis was needed to advance it to clinical trials.  Ultimately, process chemists for Novartis 
developed an approach that is a hybrid of both Smith and Paterson’s routes.61–65  In general, the 
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 Smith route, including the usage of common precursor 6, was utilized to form each of the three 
fragment regions.  The Paterson methodology was responsible for late stage elaboration in the 
C1-C9 region.  A very brief overview is provided below, in Figure 10.  The efforts of the 43 
Novartis chemists involved in this project culminated in about 60 g of pure discodermolide, 
synthesized over a total of 39 steps. 
 
 
Figure 10. A summary of the approach taken by Novartis in their large-scale synthesis of 1. 
 
1.4 STRUCTURE ACTIVITY RELATIONSHIPS FOR DISCODERMOLIDE 
1.4.1 Overview 
In order to probe and optimize the biological activity of discodermolide, numerous SAR studies 
have been carried out.  The results from analogue studies have allowed for the development of an 
extensive molecular activity map for the compound and for further optimization of binding 
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 conformation profiles.56,81  In order to simplify the analysis, the backbone of the discodermolide 
framework has been divided into three structurally distinct regions: the carbamate region in blue, 
the linker region in yellow, and the lactone region in yellow (Figure 11).  Due to the variable 
antiproliferative activity in different cell lines and small changes from study to study, an 
exhaustive list of IC50 values have been provided in a table (see Appendix) in their raw form and 
also relative to the parent compound for that particular study or cell line. 
 
 
Figure 11. Distinctive regions of discodermolide for SAR analysis. 
 
1.4.2 Carbamate Fragment Analogues 
Biological studies on discodermolide analogues have demonstrated the potential for great 
simplification and alteration to the carbamate portion of the molecule.  Manipulation of the diene 
portion of the molecule was relatively well tolerated (Figure 12, Tables 3 and 8).7,82–87  
Hydrogenation of a single olefin was associated with a slight improvement in IC50 and also 
removes a potential site for phase I metabolism (38, 39).11  However, with complete saturation 
(41), the compound lost significant potency in resistant cell lines.  Addition of the bulky 
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 photoaffinity probe (48, 49) during conformational studies did not reduce activity in A549 cells, 
but complete replacement of the group with a benzyl or phenyl ether (42, 43) significantly 
reduced its potency.  This suggests the necessity of at least one olefin in this region, and also the 
ability to add bulky groups at the C24 position. 
 
 
Figure 12. Modifications to the terminal diene. 
 
Using large, mostly aromatic substitutions, the Smith group probed the electronic and 
steric limitations of the carbamate group at C19 (Figure 13, Tables 3 and 8).85,88  Curiously, these 
analogues retained a significant degree of their potency, maintaining single or low-double digit 
nM IC50 values.  The most potent of these was the dimethylaniline moiety, whose potency was 
significantly greater than that of discodermolide in all cell lines except NCI/ADR.  This scaffold 
is known to be metabolized rapidly in vivo by cytochrome P450, however.  Less metabolically 
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 labile isosteres, like imidazole 53 and morpholine 54, did not have equivalent potency.  
Paclitaxel-discodermolide hybrid compounds 56-60 developed by Horwitz and Smith were 
appended with photoaffinity probes in order to study it’s binding mode.89  These compounds all 
had enhanced antiproliferative activity of up to 8-fold compared to the parent.  Further, the 
correlation between tether length and activity suggests that the groups are interacting with an 
aromatic pocket within tubulin rather than just enhancing the overall hydrophobicity of the 
compound. 
 
 
Figure 13. Modifications to the C19 carbamate group. 
 
Other modifications to the carbamate region have also been extensively studied (Figure 
14, Tables 3 and 8).7,84,90–93 Complete removal of the methyl groups at C16 (62) or C14 (64), or 
of the carbamate group entirely (65) resulted in compounds with low nanomolar antiproliferative 
activity similar to the parent.  For unknown reasons, though, these compounds are relatively 
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 inactive in the NCI/ADR multidrug-resistant cell line.  Epimerization of C16 or C17 in this 
region (63, 66) significantly decreased activity, emphasizing the ability of these elements to 
maintain the conformational preferences of the molecule.  More drastic alterations to the 
backbone included replacement of the C13-14 olefin with an amide linker (68) that resulted in 
sub-micromolar potency in A549 cells.  In their efforts to attach an affinity binding probe to 
discodermolide, the Schreiber group explored extensions of C17 and C16.  Whereas C17 
tolerated the group with only a slight drop in cytotoxicity (71), C16 extensions such as 73 were 
not at all active.   
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Figure 14. Modifications to the carbamate fragment. 
 
1.4.3 Linker Fragment Analogues 
In the final HCl-mediated global deprotection step of the Novartis synthesis, compounds 75-80 
were isolated (Figure 15, Tables 4 and 9).94 Of these, only 77 retained a modest potency 
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 compared to the parent.  Replacement of the C14-15 olefin and C14-methyl group with 
cyclopropane yielded a compound that was only 1-3 fold less active in MCF-7 and SKOV-3 
cells, but significantly less active in the NCI/ADR multidrug resistant line.95  This was 
comparable to the activity of the 14-normethyl analogue (64).  It was hypothesized that the A1,3-
strain imposed by the C14 methyl may be necessary to maintain a bioactive conformation that 
confers activity in MDR cell lines.95 
 
 
Figure 15. Cyclization of the linker region of discodermolide. 
 
1.4.4 Lactone Fragment Analogues 
One of the most valuable findings in the many SAR studies of discodermolide was that the 
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 structure of the lactone moiety could be drastically altered while still preserving low nanomolar 
antiproliferative activity (Figure 16, Tables 5 and 10).26,84,90,91,96–98  Even contraction of the ring 
to form butyrolactone 89 yielded a compound that was more active than the parent.  Forming a 
much-simplified lactone fragment through sequential removal of substituents in the C2-C7 
region and hydrogenation (83-93, 95) lead to compounds with improved or equivalent potency. 
Epimerization of the same stereogenic centers (90-94), however, led to a decrease in potency for 
all except analogue 93.  The lactone of the parent is known to adopt a twist-boat conformation, 
where substituents maintain an equatorial orientation and the overall ring is nearly planar.90,99  
Here, the olefin rigidifies the ring, and the double epimerization at C4 and C5 in 93 presumably 
allows the lactone to maintain its near-planarity.  
More drastic alterations to the backbone of the lactone further demonstrated how tolerant 
it was of substitution and simplification.  Outright removal of the C7 hydroxyl (88) only slightly 
reduced its cytotoxicity, and acetylation of hydroxyl groups present in this region yielded 
compounds with enhanced cytotoxicity (96-99), showing that H-bonding ability is not necessary 
for conformational requirements or binding interactions with tubulin.  Surprisingly, thiophenyl 
acetals 100 and 101 had equivalent potency to discodermolide, regardless of their orientation.  
Even the naturally occurring linear methyl ester 102 retained double-digit nanomolar potency.  
In polymerization studies carried out by Smith and Horwitz, it was shown that several 
analogues including 84 had a decreased ability to hypernucleate tubulin assembly.90 For instance, 
average MT polymer length for cells treated with 84 were 5.1 µM, which is more similar to 
Taxol (3.3 µM) than to discodermolide (0.78 µM).  It still remains unclear which structural 
features are responsible for making discodermolide so efficient at microtubule polymerization 
when compared to paclitaxel, or what affect this has on cytotoxicity. 
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Figure 16. Synthetic analogues of the lactone group. 
 
Progressing from the point mutations shown in Figure 16, more streamlined aromatic fragments 
were chosen to mimic the planar nature of the lactone in the parent (Figure 17, Tables  5 and 
10).84,85,100–103  With the exception of 121 and 122, all of the fragments shown in Figure 17 also 
have the C7 hydroxyl group removed.  Initial studies using the phenyl (103) and phenol (108) 
groups revealed sub-micromolar IC50 values, but attempts at lead-optimization – regardless of 
steric or electronic manipulations – did not improve this value significantly or help to further 
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 elucidate SAR for the region.  The exception to this was the coumarin fragment (120), which 
showed antiproliferative activity equivalent to discodermolide.  Both analogues containing a 
meta-hydroxyl substituent also performed well (108 and 121), suggesting that hydrogen bonding 
ability at this position may help improve activity.  To date, 120 is the simplest substitution for 
the lactone region that allows the overall compound to maintain its low-nanomolar activity.   
 
 
Figure 17. Streamlined analogues of the lactone group containing aromatic rings. 
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 1.4.5 Analogues with Multiple Regions of Alteration 
As more was learned about the SAR of discodermolide, more analogues were synthesized that 
incorporated several modifications into one structure.  Major alterations to the compound often 
produced inactive species, but this was not always the case.  In one of the most extreme cases of 
structural modification, truncated molecules 124-127 displayed relatively little inhibition, 
showing that both the lactone and the carbamate fragments are necessary to inhibit cell growth 
(Figure 18, Tables 6 and 11).82,84,86,93,101 
 
 
Figure 18. Truncation of the discodermolide backbone. 
 
Complete saturation of the olefins within the carbon backbone resulted in the slight loss of 
activity for that congener (128).93 However, nanomolar activity comparable to that of 
discodermolide was obtained when just one of these olefins was retained (129).  Subsequent 
removal of the C7 hydroxyl group (130) severely reduced the cytotoxic activity observed (Figure 
19, Tables 6 and 11). 
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Figure 19. Saturation of discodermolide olefins. 
 
It was hoped that acetylation of various hydroxyl groups would lead to a greater understanding 
of the electronic requirements for discodermolide’s activity (Figure 20, Tables 6 and 
11).84,93,98,104  However, compounds 132-135 displayed a significant loss in activity compared to 
the parent.  Compound 131 maintained a moderate, sub-micromolar, cytotoxicity.  This 
difference is likely due in part to the acetylation of the C17 hydroxyl, which has been shown to 
severely lower activity (see Figure 14, 67).7 
 
 
Figure 20. Acetylation of alcohol groups present in discodermolide. 
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 Knowing that 14-normethyldiscodermolide and a saturated C-24 terminus did not 
negatively impact cell growth inhibition independently, these changes were paired with various 
lactone isosteres (Figure 21, Tables 6 and 11).77,102  Improved activity was found with 
demethylation at C2 of the unsaturated fragment 137 when compared to 136.  A striking lack of 
activity was observed in the aromatic fragments assayed.  This was surprising, especially 
considering that the corresponding phenol analogue (Figure 17, 108) was so potent.  Knowing 
how potent the previously-studied coumarin derivative was, a series of analogues were 
synthesized to probe the orientation and electronic requirements for the group.  When combined 
with modifications to C14 and C23-24, only coumarin 141 displayed enhanced biological 
properties when compared to discodermolide. 
 
 
Figure 21. Investigation of lactone modifications coupled with C14 and/or C23-24 alterations. 
 
In a series of studies within the Curran and Day groups, C14 demethylation was paired 
with modifications of the lactone and/or carbamate fragments.24,103,105,106   These studies began 
 43 
 with the replacement of the lactone ring with a simple ester (Figure 22, Tables 7 and 12).24,105  Of 
the compounds studied 146-173, only seven showed activity below 5 μM in at least one cell line 
assayed.  The analogues shown in Figure 22 fared much worse than the previously-studied open-
lactone analogue, 102.  These results suggest that the poor activity may be due to the high degree 
of modification across the compound or to the oversimplification of the lactone region, and not 
merely because of the open-lactone modification itself. 
 
  
Figure 22. Carbamate and linker region modifications paired with a ring-opened lactone.  
 
Although many of the compounds in Figure 22 exhibited µM GI50, in vitro bovine brain tubulin 
assembly assays showed them to be extremely weak tubulin hypernucleators.24,105  This 
conflicting data prompted further investigation in the form of a high content cell-based assembly 
assay, which confirmed that the cells were indeed mitosis-blocking and cytotoxic.  Results such 
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 as these highlight difficulties that have been encountered when assaying discodermolide and its 
analogues; variations in activity are common across tubulin isotypes, cell lines, and in vitro 
assays. 
Collaborators Day and Curran then moved on to manipulate further regions of the parent, 
leaving the lactone moiety largely intact (Figure 23, Tables 7 and 12). When the lactone motif 
was replaced with a simple ester, activity plummeted.  Of the analogues shown in Figure 23, 
Replacement of the diene terminus (176, 177, 179-182) led to a substantial drop in activity.  
Notably, MOM protection (175) of the C3 hydroxyl group led to enhancement of growth 
inhibition while retaining sub-micromolar activity.  This was presumably due to the extension of 
the lactone’s H-bond acceptor that promoted a conformation with carbamate and lactone regions 
in close proximity.   
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Figure 23. Carbamate and lactone fragment modifications. 
1.4.6 SAR Summary 
Although discodermolide itself contains a great deal of complexity, analogue synthesis and SAR 
studies have proven that not all of components are essential for maintaining its biological 
activity.  The ability to simplify various elements of the structure without diminishing its 
antiproliferative activity makes discodermolide an interesting target for further synthetic studies.  
Furthermore, alterations like these can be used to enhance metabolic stability, a likely cause of 
failure in Phase I clinical studies.10,11  While the shortest linear sequence achieved during total 
syntheses is only 17 steps, this number reflects the convergence of the approach and is 
misleading when considering the complexity of the overall process.  SAR studies such as these 
highlight the opportunity for significant simplifications to the structure – and, therefore, the 
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 synthesis – that will help to enhance its clinical viability.  A summary of the SAR profile of 
discodermolide is shown below, in Figure 24. 
 
 
Figure 24. Summary of the SAR profile for discodermolide. 
1.5 MODELING STUDIES OF DISCODERMOLIDE 
Although there are 13 stereogenic centers and numerous rotatable sigma bonds, early modeling 
studies showed the three-dimensional conformation of discodermolide to be relatively rigid.2,107  
In 2001, the Smith group carried out energy minimization and NMR studies of discodermolide in 
CD3CN, concluding that the structure in solution was very similar to that of the solid state 
(Figure 26, top).107 Acetonitrile was chosen in order to maximize the stability of the compound 
while mimicking the inherent polarity of an aqueous biological environment.  Even though the 
experiments were carried out in solution, the helical conformation is structurally enforced in 
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 order to minimize A1,3-strain at C8-9, C13-14 and C21-22, and also syn-pentane interactions at 
C10-12, C16-18 and C18-21 (Figure 25).  
 
 
Figure 25. Conformational preferences are determined by strain minimization. 
 
In the same year, the Snyder group also carried out NMR studies to determine the 
dynamic properties of discodermolide in solution.99 These 2-D and NAMFIS (NMR analysis of 
molecular flexibility in solution) experiments were carried out in DMSO-d6 to identify 
Boltzmann populations of rotamers in solution.  They argued that a single solution conformation 
(as determined previously by the Smith group) was likely the result of signal averaging and 
represented a “virtual conformation” as a geometric average of distinct conformers.  The group 
proposed a series of 14 rapidly interconverting structural conformations that are present in 
DMSO, with 68% of the population being described as having a corkscrew-like conformation 
(Figure 26, bottom).  
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Figure 26. Conformational models of discodermolide. 
 Top: Smith’s solution structure in CD3CN (red) compared to the x-ray crystal structure (blue); bottom: Snyder’s 
corkscrew solution structure in DMSO-d6; right: Three-dimensional model of discodermolide in the binding site, 
based on HQSAR screen.  Fragments that were found to correlate with high cytotoxicity are labeled. Image at top 
left adapted with permission from Ref. 107, copyright 2001 American Chemical Society; image at bottom left 
adapted with permission from Ref. 99, copyright 2001 American Chemical Society; image at right reproduced with 
permission from Wiley-VCH Verlag GmbH & Co. KGaA, Ref. 108, copyright 2009. 
 
Using more advanced spectroscopic and modeling techniques, several groups were later 
able to develop more precise models for conformation and binding.  Competition binding 
experiments and photoaffinity labeling of discodermolide analogues provided confirmation that 
the preferred binding site of discodermolide was indeed the taxane site on tubulin, although 
multiple conformational contacts were not.45,109,110  Later analogue studies involving paclitaxel-
discodermolide-dictyostatin hybrids showed a decrease in activity, suggesting that this 
conclusion may not have been wholly accurate.111  Previously-discussed HDX experiments by 
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 Horwitz and Smith demonstrated that stabilized MT conformations differed, with solvent-
exposed lateral sites that were only observed with discodermolide treatment.22  This highlights 
difficulties that docking studies on MT stabilizers have experienced, largely as a result of 
reliance on the 3.5 Å resolution electron microscopy-derived structure of paclitaxel bound to the 
αβ-tubulin dimer (Shown in Figure 7).112 Specifically:89 (a) the MT backbone was likely 
distorted in the presence of paclitaxel, so does not precisely reflect the unbound structure; (b) Zn-
induced crystalline sheets have been shown to have different conformations than those found in 
vivo; (c) the M-loop region, which is involved in paclitaxel binding, is poorly resolved; (d) 
lateral contacts between protofilaments are not present due to the aggregation state of the sample; 
(e) bovine brain tubulin was used to obtain this sample, although this tubulin isotype is different 
than that which is found in humans. 
A study conducted by Dias and Andricopulo assembled a virtual set of fragments to 
develop a predictive quantitative SAR model (Hologram QSAR, or HQSAR).108  This type of 
study differs significantly from others in that the researchers sought to develop a training set that 
could be used to predict IC50 values and highlight structural features that were important for 
biological activity.  Using their computational results and the PDB entries for bound paclitaxel 
and epothilones A (PDB IDs 1JFF and 1TVK, respectively), they were able to construct a three-
dimensional model of discodermolide in the binding site.  This model is shown in Figure 26 
(right).  The model agreed with previous studies that gave discodermolide a U-shaped structure, 
and placed the linker region away from the binding pocket. 
Nine years after their original single-force field conformational analysis, the Snyder 
group suggested a pose for discodermolide in which the linker region pointed away from the 
binding site (Figure 27).113  This came after extensive modeling using NAMFIS and docking 
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 experiments with Glide, RosettaLigand, and AUTODOCK software.  Specifically, C3 and C17 
hydroxyl groups and the carbamate group form polar contacts with the M-loop while several 
nonpolar contacts to Leu361 are made with hydrophobic groups.  The model was consistent with 
SAR data from known analogues and non-resistance to various cell lines containing β-tubulin 
mutations.9  It also provided an alternative to established models, which could not always be 
used to rationalize SAR results.  One of the most striking outcomes of these experiments is the 
understanding that major alterations, such as removal of hydroxyl groups or truncations of the 
structural backbone, would be possible without great loss of activity.  Assuming that binding 
interactions were maintained, such alterations could be employed to improve the 
pharmacokinetic profile and enhance the viability of discodermolide as a therapeutic agent. 
 
 
Figure 27. Proposed binding conformation of discodermolide.  
Polar contacts are highlighted in black and nonpolar contacts are highlighted in magenta.  Reproduced with 
permission from Ref. 113, copyright 2010 American Chemical Society. 
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 2.0  RESEARCH PROJECT OVERVIEW 
2.1.1 Hypothesis 
Our group’s interest in pursuing SAR development in this area was spurred by the need to further 
investigate the role of discodermolide’s linker region.  The majority of the SAR data for the 
linker has been collected from naturally occurring congeners or byproducts obtained during the 
course of other studies.  As mentioned, it has been proposed that the linker region points away 
from the binding site while positioning the carbamate and lactone regions into it (Figures 26 and 
27).113  Further information is limited without a crystal structure of discodermolide in its tubulin 
binding pocket.   
HQSAR studies were initially carried out by Mr. Daniel Brody of the Day lab in 
collaboration with the Andricopulo group to determine if significant alterations to the linker 
region could be made while maintaining the appropriate positioning of the carbamate and lactone 
regions.114  Pleasingly, these computational models suggested that modifications to the linker 
portion of discodermolide may be well-tolerated. Based on the top hits of the HQSAR results, 
several virtual analogues were identified that allowed the carbamate and lactone regions to align 
well with the parent despite major structural changes.  The best of these were predicted to have 
IC50 values of ~100 nM against A549 lung carcinoma cell types in at least 3 of the 4 parameter 
models studies (Figure 28).   
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Figure 28. Discodermolide compared to the top performing hits from Day group HQSAR experiments.  Modified 
regions are circled on the analogues.114 
 
These promising results prompted further investigations with the long-term goal to 
synthesize simplified discodermolide analogues with novel linker regions and to assess their 
biological profiles. These analogues would be constructed with streamlined and more 
metabolically stable carbamate and lactone fragments.  Two parallel projects were initiated in the 
Day group: 
1) Replacement of C8-C14 with a truncated olefin linker (as shown in Figure 28). 
2) Replacement of C8-C14 with a linker formed through multicomponent reactions. 
The second of these two initiatives will be discussed at length herein. 
Multicomponent reactions are atom-economical processes that have the potential to 
increase efficiency and variability when compared to traditional reaction sequences (Figure 
29).115,116 Although such reactions have been used frequently to construct complex 
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 pharmacological agents, they have only recently been applied towards the synthesis of more 
elaborate natural products.117  Isocyanide-based MCRs can provide a large library of drug-like 
molecules from a relatively small set of starting materials.  The Ugi four-component reaction 
(Figure 29a) typically combines an isocyanide, a carbonyl-containing compound such as an 
aldehyde or ketone, an amine, and an acid in one pot to irreversibly deliver an α-acylamino 
amide.118,119  The van Leusen protocol (Figure 29b) involves treatment of a tosylmethyl 
isocyanate with an aldehyde and a primary amine leading to a 1,4-disubstituted imidazole.120  
 
 
Figure 29. Reaction summary for (a) Ugi and (b) van Leusen MCR approaches. 
 
 
2.1.2 Planned Research Approach 
These two types of MCRs were envisioned to produce a series of discodermolide analogues with 
novel linker regions (Figure 30).  First, carbamate and lactone fragments would need to be 
synthesized containing either an acid or amino terminus.  Immediately before the Ugi MCR was 
carried out, the amino fragments could be converted to the less stable isocyanide and then paired 
with the other components to produce the product.  In this way, MCR processes would be used to 
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 join the carbamate and lactone regions together through either a peptide-like or imidazole 
linkage.  
 
 
Figure 30. Design of discodermolide analogues joined by a linker through MCR. 
 
The goal of this project was to construct precursor carbamate and lactone fragments 
containing amine and acid termini for later MCR coupling.  Synthetic targets for the carbamate 
and lactone fragments were selected for their proven successes in previous SAR studies and 
simplicity of structure rather than pharmacological novelty (Figure 31, 187-189, 192-195).  The 
imidazole linker formed through the van Leusen protocol (Figure 31, 190) was chosen as an 
isostere for the truncated olefin linker used in our group’s HQSAR experiments.114  It also retains 
the ability to hydrogen bond, which has been hypothesized to aid in binding site interactions 
between tubulin and discodermolide.22  The peptide-like Ugi linker (Figure 31, 191) is much 
more flexible than that of the parent.  However, the tertiary amide can be substituted with a 
bulky group such as isopropyl to impose a conformational bias.  SAR studies have shown that 
some additional steric bulk is well-tolerated in this region, and according to the Snyder model 
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 would be pointing away from the binding site, so this change would not likely have any steric 
effect on binding to the MT.84  If necessary, interchanging the substituent at this position would 
be a straightforward method to manipulate PK properties such as solubility. 
 
 
Figure 31. Fragments initially identified for this project’s analogue studies. 
 
Use of a multicomponent approach would allow for the synthesis of a broad variety of 
analogues through variation of the carbamate and lactone regions.  For instance, a single 
carbamate fragment could be paired with any or all four of the lactone fragments shown above in 
parallel MCR experiments to yield up to four new analogues.  Another advantage of the 
multicomponent approach is that the linker region could effectively be flipped through strategic 
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 assignment of amine and acid components, as shown in Figure 32.  The ability to construct a 
wide array of analogues through MCR was initially enticing, as was the novel nature of the 
linker region for discodermolide analogue synthesis. 
 
 
Figure 32. Sample analogues resulting from (a) van Leusen and (b,c) Ugi reactions.  
 
In the first phase of this project, representative computational models were constructed to 
assess the three-dimensional conformations of the proposed analogues.  Because the orientation 
of carbamate and lactone regions in the binding site is thought to be important, the configuration 
 57 
 of the analogues should closely match that of the geometrically rigid parent structure.  In the 
second phase of this project, a variety of MCR precursors were synthesized.  A functionalized 
lactone containing the requisite stereotriad found in discodermolide was first synthesized as a 
common precursor to carbamate fragment analogues. This set the stage for the further carbamate 
fragment syntheses.  Later work by Mr. Daniel Brody in the Day lab showed that this approach 
was feasible, successfully transforming the same common precursor lactone (196) into carbamate 
fragment 197 in 10 steps (Scheme 12).114   
 
 
Scheme 12. Transformation of common precursor 196 into an advanced carbamate fragment.114 
 
With the common precursor 196 synthesized and further carbamate fragments being explored 
elsewhere in the Day group, focus shifted to discodermolide’s lactone region.  Here, five lactone 
region fragments that contained amine or acid termini and one additional advanced fragment 
were successfully and efficiently completed.   
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 3.0  RESULTS AND DISCUSSION 
3.1 CONFORMATIONAL MODELS OF DISCODERMOLIDE ANALOGUES 
Prior to the synthesis of individual fragments, a computational model of representative analogues 
was carried out.  One of the fundamental characteristics of discodermolide is its relatively rigid 
framework, and the Snyder binding model postulates that the positioning of the carbamate and 
lactone regions specifically is crucial for its biological activity.113 Therefore, the positioning of 
the carbamate and lactone regions in these analogue models needed to mimic that of the parent in 
order for them to be viable candidates for this MCR strategy. 
Preliminary MM2 simulations of proposed analogues were conducted using Chem & Bio 
3D 12.0 software.  These computational models take into account factors that introduce strain or 
steric energy, including: bond stretching and bending, torsional strain, van der Waals 
interactions, and electrostatic interactions.  The thermodynamic global minimum conformation 
from the MM2 experiment was then exported to MacPyMOL for rendering and visualization.  
Finally, the analogue structure was superposed on that of discodermolide and the three-
dimensional space they occupied was compared. 
Shown in Figure 33 are the structures and overlays that are the result of these 
computational models.  In the three analogues shown, carbamate and lactone fragments are 
constant while the linker region is systematically altered.  Only the linker region is then 
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 responsible for any conformational differences between the three.  Shown on the left is the 
product of a van Leusen reaction (198) and in the center and right are two Ugi reaction products 
(199 and 200).  Pleasingly, the analogues exhibited a high degree of overlap with the parent, 
despite having structurally dissimilar linker regions, truncated carbamate fragments, and 
simplified lactone regions.  This conformational similarity was encouraging and so the next 
phase of the project was initiated. 
 
 
    
Figure 33. Overlay of sample MCR analogues 198-200 and discodermolide (white). 
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 3.2 SYNTHESIS OF A CARBAMATE FRAGMENT COMMON PRECURSOR  
A common precursor synthetic approach towards discodermolide has been used by a variety of 
groups in order to take advantage of its repeating stereotriad (see Chapter 1.3).  This stereotriad 
has been shown to be essential for biological activity to remain intact (see Figures 14 and 16).  
Within the Day group, Mr. Daniel Brody had shown this strategy to be an effective means to 
obtain carbamate analogues in a parallel analogue synthesis project (see Scheme 12).  In order to 
form this common precursor lactone 196, a strategy developed within the Day group and by 
Novartis was employed (Scheme 13).121,122 
 
 
Scheme 13. Synthesis of a discodermolide common precursor lactone. 
 
Beginning with commercially available chiral oxazolidinone 201, deprotonation with n-
butyllithium and acylation with propionyl chloride led to the formation of the aldol precursor 202 
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 in 59% yield.123  Carboximide 202 was transformed into a boron enolate with 
diisopropylethylamine and dibutylborontriflate, and immediately treated with methacrolein to 
produce 203 as a mixture of syn and anti adducts in a ratio of about 9:1.  This ratio was 
determined through the calculation of vicinal coupling constants for the alpha and beta protons in 
the product’s 1H-NMR spectrum (syn: 3JHH = 3.0 Hz).124,125  The desired syn isomer was then 
easily isolated via flash chromatography in a 69% overall yield.  Alkoxy oxazolidinone 203 was 
protected as a silyl ether and isolated in 89% yield without need for further purification. 
Treatment of the alkene moiety of 204 with 9-BBN and then peroxide provided the 
hydroboration-oxidation product 205.122  This unstable hydroxy imide was then immediately 
cyclized upon exposure to potassium tert-butoxide, giving lactone 196 in 67% yield over two 
steps.  Overall, a single isomer of this common precursor was synthesized in 5 steps with a 24% 
yield.  From here, the lactone 196 could serve as a key intermediate during the synthesis of 
carbamate fragment analogues. 
3.3 SYNTHESIS OF LACTONE FRAGMENT PRECURSORS 
3.3.1 Summary of Fragment Syntheses 
Once the carbamate region’s common precursor had been synthesized, focus shifted towards the 
lactone region of discodermolide.  Due to the variable stability of isocyanide compounds, the 
final two-step transformation of amine to isocyanide was strategically delayed until all other 
fragments were ready for MCR.  Thus, the immediate substrates targeted for synthesis contained 
acid or amine termini.  Overall, five fragments were completed, as summarized in Table 1 below. 
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Table 1: Summary of acid and amine lactone fragments syntheses. 
 
 
3.3.2 Synthesis of the 3-(2-Hydroxypropyl)phenol Fragment 206 
Although the lactone region is known to interact with the MT binding pocket, there is a 
surprising amount of flexibility in the structural modifications that are allowed (see Figure 16).  
A m-hydroxy phenol substitution for the lactone isostere would enable hydrogen-bonding 
interactions that mimic the C3-hydroxyl group or the endocyclic oxygen of the parent.  By itself, 
this substitution has been successful in SAR studies (108) but when combined with additional 
modifications, activity diminished to less than 17 times that of the parent (138).77,100  The 
potential for an incredibly streamlined analogue was deemed worth that risk, and synthesis of 
MCR components was begun. 
Initially, a cost-effective approach was taken towards the synthesis of phenol fragment 
206.  Starting from the commercially available eugenol (213), successive phosphate protection 
and deprotection were used to yield the m-methoxybenzene intermediate 214 (Scheme 14).  
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 Unfortunately, while 215 could be obtained in yields as high as 43%, the quantity recovered was 
often below 30%.  A second-generation scheme was developed to circumvent the inconsistency 
of this approach and precautions associated with phosphate group removal on large scale. 
 
 
Scheme 14.  First-generation synthesis of fragment 206 via dihydroxylation. 
 
This new route took advantage of the inherent chirality of the commercially-available (S)-
(+)-epichlorohydrin (218) to establish the stereochemistry of the β-hydroxy group of 206.  In a 
first attempt, Grignard reagent 217 generated in situ was reacted with 218 to provide 
chlorohydrin 219, then immediately reacted with sodium hydroxide to produce epoxide 220 in 
only 30% over two steps.  A second attempt employing commercial Grignard reagent 217 and 
copper (I) cyanide significantly improved the efficiency of the process, increasing the yield to 
99% for the first step (Scheme 15).  The resulting chlorohydrin 219 was then treated with sodium 
hydroxide to produce epoxide 220 in 74% yield via an intramolecular SN2 reaction.  Finally, the 
reaction of 220 with ammonium hydroxide gave the final β-hydroxyamine fragment 206 in 88% 
yield. 
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Scheme 15. Second-generation synthesis of β-hydroxyamine 206 via an epoxide intermediate. 
 
 
3.3.3 Synthesis of 3-Propylphenol Fragments 
Early investigations by Smith and co-workers demonstrated that the β-hydroxy group of the 
phenol analogue was not necessary to maintain significant biological activity (Figure 17).100  
Despite the loss of a potential hydrogen bonding partner, analogues explored by the Smith group 
such as these maintained an IC50 of sub-200 nM in A549 and MCF-7 cells.  Therefore, efforts 
were also made to synthesize a β-dehydroxy complement (208 and 209) to β-hydroxyamine 
fragment 206 described in the previous section.   
A convergent strategy was used here to synthesize both acid and amine fragments from 
alcohol intermediate 218 (Schemes 16 and 17).  A Grignard reaction coupling 217 with allyl 
bromide went smoothly on a multi-gram scale, producing 215 with a 97% yield after flash 
chromatography.126  This was followed by a regioselective hydroboration reaction of 215 with 9-
BBN and then peroxide that yielded alcohol intermediate 218 in 67%.126  From here, TEMPO-
mediated oxidation provided acid 207 in 97% yield.127   Overall, the transformation required only 
three steps and produced the desired acid fragment 207 in 62% yield. 
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Scheme 16. Synthesis of acid fragment 207. 
 
From that same alcohol intermediate 218, two routes were followed to obtain azide 221, the 
precursor to the desired amine fragment 208 (Scheme 17).  Many options are known for such 
functional group transformations as alcohol to amine.  The simultaneous exploration of both 
routes was carried out in order to explore two of these options and determine which was most 
efficient.  In the first route, alcohol 218 was reacted with triphenylphosphine and iodine to form 
iodide 219 in 84% yield.  In this reaction, nucleophilic attack of the hydroxyl group on 
iodotriphenylphosphonium iodide results in the formation of an oxyphosphonium, which can 
then be displaced through substitution by in situ generated iodide anion.128  Iodide 219 was then 
subjected to nucleophilic substitution by sodium azide to yield azide 221 in 75% yield.  In the 
second route, the alcohol 218 was first protected through treatment with mesyl chloride to form 
mesylate 220.  This intermediate was then displaced by sodium azide to form 221 in 76% over 
two steps.129  Overall, the second route was the more efficient of the two, and was used in later 
scale-up reactions.  In order to form the desired amine, the azide 221 produced from these two 
routes was then reduced triphenylphosphine.  This final reaction was sluggish and produced the 
target amine 208 in 37%, with the majority of unreacted starting material easily recovered.   
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Scheme 17. Two routes towards the synthesis of amine fragment 208. 
 
3.3.4 Synthesis of Coumarin Fragments 
The impressive biological activity of 7-subsituted coumarin analogues of discodermolide 
demonstrates that this motif mimics that of the parent despite its simple structure (Figures 17 and 
21).99,102,107  Substitution at the 7-position is crucial (see Figure 21), presumably because it 
allows for proper alignment of the internal ester within the binding site.  Overall, this is the most 
streamlined fragment of those being synthesized. 
The synthesis of coumarin fragments with both acid (209) and amine (210) termini was 
undertaken.  The formation of acid 209 was carried out in a straightforward 2-step process.  First, 
bromination of 7-methylcoumarin using NBS and catalytic benzoyl peroxide gave bromide 223 
in 73% yield.  Although this yield is reported for the purified bromide 223, the succinimide-
contaminated crude product could also be used without further purification in the following step.  
With the bromide in hand, treatment with sodium nitrite and acetic acid provided the desired acid 
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 fragment 209 in 81% yield.  This reaction involves the initial displacement of the bromide by 
sodium nitrite.  Under acidic conditions and in the presence of excess sodium nitrite, the 
nitroalkane intermediate becomes protonated, enabling the stepwise formation of the 
corresponding nitrolic acid, nitrile oxide, and then hydroxamic acid, which is finally hydrolyzed 
to yield the desired carboxylic acid.130  
 
 
Scheme 18. Synthesis of the 7-carboxycoumarin fragment 209. 
 
From the bromide intermediate above (223), amine fragment 210 could also be rapidly 
synthesized.  Initially, the Delépine protocol was used to form the amine through the reaction 
with hexamethylenetetramine to form the corresponding quaternary ammonium salt and 
immediate acid hydrolysis to convert the salt into amine 210 (Scheme 19, top).131,132 On a 200 
mg scale, this reaction was carried out in one step in a 99% yield.  However, the method suffered 
from reduced and inconsistent yields during the scale-up process.  Therefore, a pathway 
modified from 17 that relied on an azide intermediate was explored.   
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Scheme 19. Synthesis of the 7-aminocoumarin fragment 210. 
 
Bromide 223 was treated with of sodium azide, sodium iodide and the phase transfer 
catalyst tetraethylammonium bromide to gave azide 224 in quantitative yield via nucleophilic 
displacement of the in situ-generated iodide intermediate (Scheme 19, bottom).  Staudinger 
reduction of azide 224 provided the completed amine fragment 210 in 11% yield.133  This second 
pathway could be carried out on a multi-gram scale, but suffered from low yields due to poor 
solubility of the coumarin substrate in the reaction solution.  Fortunately, much of the unreacted 
azide 224 could be easily re-isolated following completion of the Staudinger reaction. 
 
 
3.3.5 Synthesis of 6,2-Normethyl-2,3-anhydro Lactone Fragments 
The 2-normethyl-2,3-anhydro motif 195 was selected for its simplified structure and improved 
activity when substituted into the discodermolide framework (85, Figure 16).96  While the lack of 
a C3-hydroxyl would prevent a potential H-bonding interaction with Pro272 within the binding 
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 site, the Snyder model suggests that this could be overcome by higher-affinity hydrophobic 
interactions with tubulin’s M-loop.113  Another advantage is that when discodermolide’s lactone 
region is substituted with this motif it becomes more cytotoxic in multi-drug resistant NCI/ADR 
cells.96  The synthesis of this fragment was designed to enable late-stage differentiation for both 
the truncated olefin and the MCR synthetic routes from lactone 196 (Scheme 20).77  Following 
the formation of this advanced intermediate, MCR fragments could be formed through PMB 
deprotection and subsequent functional group manipulations of the resulting alcohol using routes 
modified from those shown in Schemes 16 and 17. 
 
 
Scheme 20. Synthesis of the 2-normethyl-2,3-anhydro fragment. 
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 The synthesis began with a PMB protection of ethyl glycolate, using PPTS as a mild acid 
to yield 226 in 89%.77  From here, the ester was reduced using DIBAL-H to furnish aldehyde 
227 in 89% yield.  This aldehyde was subjected to an allylation according to Keck’s conditions 
to form homoallylic alcohol 228.134  The secondary alcohol resulting from this reaction was 
immediately protected as a silyl ether under standard conditions.  Once the alcohol had been 
protected, focus shifted to extending the backbone of what would become the lactone ring.  As 
an alternative to ozonolysis, the terminal olefin of 229 was subjected to (diacetoxyiodo)benzene-
mediated oxidative cleavage to forming 230 in 89% yield.135  In one pot, this method results in 
dihydroxylation of the olefin under Upjohn conditions followed by transformation to the 
aldehyde upon liberation of PhI and two equivalents of AcOH.  This route enabled the advanced 
aldehyde intermediate 230 to be obtained in very high yields on a multi-gram scale (53% over 
five steps).   
Following the protocol used by the Smith group during their SAR studies, Brown 
crotylation of aldehyde 230 enabled the rapid addition of two new stereocenters and the 
formation of anti-adduct 231 in 43% yield.77  This crotylation product was isolated initially as an 
intractable mixture with the isopinocampheol byproduct of the reaction.  Attempts at performing 
the subsequent acylation reaction resulted in <10% conversion of starting material by NMR, 
likely a result of those impurities.  Similar difficulties in the separation of unwanted byproducts 
during diisopinocampheylborane-mediated allylation and crotylation reactions have been 
extensively reported, although more intensive purification processes have been met with success 
for others.136   
From intermediate 232, ring-closing metathesis would lead to closure of the lactone ring, 
and further functional group manipulations of the protected terminal alcohol would yield the 
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 desired functionalized tether.  Because of its use in previous SAR studies, this lactone-forming 
step has a synthetic precedent in the Smith group (75% using Grubbs second generation catalyst 
under standard metathesis conditions).77  Therefore, following optimization of the acylation 
product’s purification, this remaining key step would not likely hinder future synthetic efforts. 
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 4.0  SUMMARY 
The past two decades of research on discodermolide have yielded an incredible amount of 
knowledge about the compound, but still leave many questions to be answered. With a single 
digit nM IC50 similar to paclitaxel, an estimated 160-fold greater aqueous solubility than 
paclitaxel, an identified high affinity binding site, and an effectiveness even in drug resistant cell 
lines where paclitaxel and epothilone B fail, discodermolide is an extremely viable lead 
compound for future studies. The SAR profile summarized in Chapter 1 demonstrates that 
simplifying the structure of discodermolide can lead to a potent analogue with a more 
streamlined synthesis.  MCR strategies will make analogue synthesis more efficient, requiring 
only one coupling step that simultaneously establishes the linker region, and the ability to 
interchange components (carbamate and lactone fragments) to efficiently generate diversity. The 
daunting task of establishing 13 stereogenic centers, four olefins, a completely functionalized 
lactone, and managing the multiple coupling stages can therefore be eased. Finally, because 
unwanted toxicity of discodermolide in high doses is thought to stem from drug metabolites, 
analogue synthesis is a good means to explore the reasons for and mitigate this effect.   
The overarching goal of this project is to design a straightforward synthesis for 
structurally simplified fragments, and to join these via MCR chemistry to form discodermolide 
analogues with a novel linker region.  Significant progress has been made toward s the 
completion of this goal.  Once an MCR route to analogue synthesis had been decided upon, 
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 initial modeling studies helped to understand the three dimensional configuration of these 
analogues compared to that of the parent.  The high degree of overlap between proposed 
analogues and discodermolide led to the beginning of the synthetic phase of the project.   
The synthesis of five separate fragments to mimic the lactone region of discodermolide 
have been described.  These syntheses require on average only 3 steps to obtain, and have been 
carried out on a multi-gram scale.  This efficiency is of particular importance for making a drug 
synthetically feasible on an industrial scale.  The 2-normethyl-2,3-anhydro fragment is in its 
advanced stages of construction, and needs only a precedented metathesis reaction to be 
completed before functional group manipulations to differentiate between acid and amine will 
complete the sequence.  In addition, a common precursor lactone to precede the synthesis of 
carbamate fragment analogues has also been achieved. Although this project was halted 
prematurely, the MCR approach is still one that is promising for future SAR investigations of 
discodermolide. 
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 5.0  EXPERIMENTAL 
Modeling Experimental 
Model analogues, like those shown in Figure 33, were constructed using ChemDraw Ultra 12.0, 
converted to .mol format using Chem3D Pro 12.0.  From there, PyMOL was used for 3D 
rendering of analogues, overlay with discodermolide was carried out using the lactone ring and 
the carbamate stereotriad carbons with the pair fitting wizard. 
 
Synthesis Experimental 
All reactions were performed under an inert atmosphere of N2 gas in oven-dried glassware using 
anhydrous solvents, unless otherwise noted.  Methylene chloride (CH2Cl2) was distilled from 
calcium hydride. Tetrahydrofuran (THF) was obtained from sodium/benzophenone distillation.  
All other anhydrous solvents were purchased from Sigma-Aldrich.  All reactions were monitored 
by thin–layer chromatography (TLC) carried out on 0.25 mm EMD silica gel plates (60F–254) 
using heat or UV light (254 nm) for visualization and p-anisaldehyde in ethanol, or 0.2% 
ninhydrin in ethanol as developing agents. TSI silica gel (230–400 mesh) was used for flash 
chromatography.  1H- and 13C- NMR spectra were recorded on a Bruker Avance II Ultrashield 
Plus 600 equipped with a cryoprobe at 600 and 150 MHz, respectively.  Chemical shift values 
are in ppm relative to residual solvent signal.  The following abbreviations are used to indicate 
the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad.  FT-
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 IR spectra were recorded on a Bruker Alpha FT-IR spectrometer.  Low-resolution mass spectra 
were obtained on an Applied Biosciences API 2000 ESI- triple quadrupole mass spectrometer 
with a Shimadzu UFLC inlet system. Additional mass spectra were recorded on a Waters Super 
Critical Fluid Chromatograph with a 3100 MS Detector using a solvent system of methanol and 
CO2 on a Regis Cell OD column.   
 
 
 
Preparation of 202. Chiral auxiliary 201 (1.00 g, 5.64 mmol) was dissolved in THF (22.6 mL) 
and the solution was cooled to 0 °C.  Then, n-BuLi (3.9 mL, 1.6 M in hexanes) was slowly 
added, followed by propionyl chloride (0.59 mL, 6.7 mmol).  The reaction solution was allowed 
to warm slowly to r.t. and stirred at that temperature for 19 h.  The reaction was quenched 
through the addition of sat. aq. NH4Cl (23 mL).  The layers were separated, and the aqueous 
layer was extracted with Et2O (2 x 23 mL).  The combined organic layers were washed with 1 M 
HCl (2 x 23 mL), 1 M NaOH (2 x 23 mL), and brine (23 mL).  The organic layer was dried over 
MgSO4, filtered, and concentrated in vacuo.  The residue was purified by chromatography on 
SiO2 (0–100% EtOAc in hexanes) to afford 202 (0.78 g, 59%) as a faintly yellow solid.  Rf = 
0.24 (10% EtOAc in hexanes); 1H NMR (600 MHz, CDCl3) δ 7.35 (t, J = 7.2, 2H), 7.29 (t, J = 
7.2 Hz, 1H), 7.22 (d, J = 7.2 Hz, 2H), 4.70 (m, 1H), 4.22 (dd, J = 9.0, 16.8 Hz, 1H), 4.18 (dd, J = 
3.0, 9.0 Hz, 1H), 3.32 (dd, J = 3.0, 13.2, 1H), 3.03 (m, 2H), 2.79 (dd, J = 9.6, 13.8 Hz, 1H), 1.22 
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 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 174.24, 153.67, 135.47, 129.57, 129.11, 
127.50, 66.36, 55.33, 38.08, 29.35, 8.44. 
 
 
 
 
Preparation of 203. The acylated chiral auxiliary 202 (0.962 g, 4.12 mmol) was dissolved in 
CH2Cl2 (9 mL) and cooled to 0 °C before n-dibutylboron triflate (4.9 mL, 1 M in CH2Cl2) and 
DIPEA (0.93 mL, 5.3 mmol) were slowly added.  The solution was then cooled to -78 °C and 
methacrolein (0.77 mL, 9.3 mmol) was slowly added.  After stirring for 20 min, the solution was 
warmed to 0 °C and stirred an additional 1.5 h.  Workup proceeded with the addition of pH 7 
buffer (5 mL), MeOH (9 mL), and H2O2 (30% in H2O, 5 mL) in MeOH (14 mL).  The solution 
was stirred at 0 °C for 1 h, and then partially concentrated in vacuo.  The resulting slurry was 
extracted with Et2O (3 x 10 mL), the organic layer was washed with brine and dried over MgSO4 
and concentrated in vacuo.  The crude product was purified by chromatography on SiO2 (0–
100% EtOAc in hexanes) to afford 203 (0.901 g, 69%) as a single diastereomer, as a white solid.  
1H NMR (600 MHz, CDCl3) δ 7.35 (t, J = 7.2, 2H), 7.30 (t, J = 7.2 Hz, 1H), 7.22 (d, J = 7.2 Hz, 
2H), 5.13 (s, 1H), 4.99 (s, 1H), 4.73 (m, 1H), 4.43 (s, 1H), 4.26 (dd, J = 9.0, 16.8 Hz, 1H), 4.21 
(dd, J = 3.0, 9.0 Hz, 1H), 3.99 (qd, J = 3.0, 7.2 Hz, 1H), 3.29 (dd, J = 3.6, 13.8, 1H), 2.93 (d, J = 
3.0 Hz, 1H), 2.82 (dd, J = 9.6, 13.2 Hz, 1H), 1.74 (s, 3H), 1.20 (d, J = 7.2 Hz, 3H). 
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Preparation of 204. To the stirring solution of auxiliary 203 (0.754 g, 2.48 mmol) in CH2Cl2 (4 
mL) at 0 °C was slowly added 2,6-lutidine (0.40 mL, 3.5 mmol) and then TBSOTf (0.63 mL, 2.7 
mmol) dropwise.  After 2 h of stirring, an additional portion of 2,6-lutidine was added (0.40 mL), 
and stirring continued at 0 °C for an additional 1 h.  The reaction was quenched through the 
addition of 1 M HCl (4.5 mL) and hexane (9 mL).  The aqueous layer was extracted with 
hexanes (3 x 10 mL) and the combined organic layers were washed with 1 M HCl (10 mL) and 
NaHCO3.  The organic layer was dried with MgSO4, filtered, and concentrated in vacuo.  The 
crude white residue of 204 (0.924 g, 89%) was submitted for NMR analysis and used in the 
following step without further purification.  The NMR shows only slight contamination with 
compound 203 and tert-butyl dimethylsilanol.  1H NMR (600 MHz, CDCl3) δ 7.34 (t, J = 7.2, 
2H), 7.28 (t, J = 6.6 Hz, 1H), 7.22 (d, J = 7.2 Hz, 2H), 4.94 (s, 1H), 4.84 (s, 1H), 4.59 (m, 1H), 
4.36 (d, J = 6.6 Hz, 1H), 4.17 (dd, J = 2.4, 9.0 Hz, 1H), 4.15 (dd, J = 9.0, 16.8 Hz, 1H), 4.05 
(pentet, J = 6.6 Hz, 1H), 3.29 (dd, J = 3.0, 13.2, 1H), 2.79 (dd, J = 10.2, 13.2 Hz, 1H), 1.72 (s, 
3H), 1.22 (d, J = 7.2 Hz, 3H), 0.91 (s, 9H), 0.02 (s, 3H), –0.01 (s, 3H). 
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Preparation of 205.  To a stirring solution of alkene 204 (0.478 g, 1.14 mmol) in THF (3.0 mL) 
at 0 °C was added 9-borabicyclo[3.3.1]nonane (4.6 mL, 0.5 M in THF) dropwise.  The solution 
was stirred at that temperature for 15 minutes and was then allowed to slowly warm to r.t. over 
5.5 h. The solution was then cooled to 0 °C and then the following were sequentially added: a 
pre-mixed solution of EtOH (3.0 mL) and THF (3.0 mL), pH 7 phosphate buffer (3.0 mL), and 
H2O2 (30% in H2O, 3.0 mL).  The resulting mixture was stirred vigorously at 0 °C and stirring 
continued overnight at r.t.  Workup of the reaction was carried out through the addition of 
hexanes (10 mL) and Na2S2O3 (10 mL).  The aqueous layer was extracted with hexanes (2 x 10 
mL), the combined organic layers were washed with brine (10 mL), dried over MgSO4, filtered 
and concentrated in vacuo.  The crude residue of 205 (0.595 g) was submitted for NMR analysis 
to confirm the disappearance of olefin peaks (singlets at 4.94 and 4.84 ppm) and was used in the 
following step without further purification. 
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 Preparation of 196. Potassium tert-butoxide (6 mg, 0.05 mmol) was added to a solution of 205 
(0.595 g, 1.37 mmol) in THF (14 mL) and the resulting solution was stirred for 1.5 h.  The 
reaction was then diluted with hexanes (35 mL) and quenched with brine (30 mL).  The organic 
layer was then dried over MgSO4, filtered, and concentrated in vacuo.  The crude product was 
purified by chromatography on SiO2 (0–100% EtOAc in hexanes) to afford 196 (0.237 g, 67%) 
as a white solid.  1H NMR (600 MHz, CDCl3) δ 4.27 (t, J = 10.2 Hz, 1H), 4.14 (dd, J = 4.8, 10.8 
Hz, 1H), 3.68 (m, 1H), 2.64 (m, 1H), 2.20 (m, 1H), 1.30 (d, J = 7.2 Hz, 3H), 0.96 (d, J = 7.2 Hz, 
3H), 0.89 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 173.95, 73.64, 
70.24, 43.77, 30.43, 25.83, 18.11, 16.41, 12.18, –4.44, –4.63; m/z (ESI) [M + H]+ 259.1. 
 
 
 
 
 
Preparation of 214. To a stirring solution of eugenol (3.10 mL, 20.0 mmol) in CCl4 (67 mL) at 
0 °C was added diethyl phosphite (2.70 mL, 20.98 mmol).  Triethylamine was then added 
dropwise, the solution was allowed to warm to room temperature by removal of the ice bath.  
After 20 h, an additional portion of diethyl phosphite (0.39 mL, 3.0 mmol) was added.  Stirring 
was continued for an additional 24 h, after which the solution was diluted with CH2Cl2 (40 mL), 
washed with H2O (100 mL), then 10% HCl (100 mL), brine (100 mL), dried over Na2SO4, 
filtered, and concentrated in vacuo.  The residue was purified by chromatography on SiO2 (0–
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 100% EtOAc in hexanes) to afford 214 (5.087 g, 85%) as a colorless oil.  Rf = 0.44 (25% EtOAc 
in hexanes); 1H NMR (600 MHz, CDCl3) δ 7.19 (dd, J = 7.2, 1.2 Hz, 1H), 6.76 (s, 1H), 6.72 (dd, 
J = 8.4, 1.8 Hz, 1H), 5.97 (ddt, J = 17.4, 10.2, 6.6 Hz, 1H), 5.10 (dd, J = 17.4, 1.8 Hz, 1H), 5.08 
(dd, J = 10.2, 1.8), 4.26 (dq, J = 7.2 Hz, 4H), 3.85 (s, 3H), 3.35 (d, J = 6.6 Hz, 2H), 1.36 (t, J = 
7.2, 6H); 13C NMR (150 MHz, CDCl3) δ 150.56, 138.29, 137.85, 137.21, 121.21, 120.77, 
116.17, 113.10, 64.56, 56.01, 40.06, 16.21. 
 
 
 
 
Preparation of 215.  
Method A: Gaseous ammonia (~20 mL after condensation) was passed through a K2CO3 
drying tube and condensed into a dried 3-necked flask outfitted with an additional K2CO3 drying 
tube.  To this solution was added 214, and then pieces of sodium (0.427 g, 18.6 mmol), rinsed 
with dried hexanes, were added over 5 minutes.  A color change was observed, and EtOH was 
added to quench the reaction after 5 minutes.  A stream of N2 was used to remove ammonia at 0 
°C, and crude orange oil was diluted in Et2O (30 mL).  This solution was washed with H2O (30 
mL), the aqueous layer was extracted with Et2O (3 x 20 mL), and the combined organic layers 
were washed with brine (20 mL).  The resulting organic solution was dried over Na2SO4, filtered, 
and concentrated in vacuo.  The residue was purified by chromatography on SiO2 (0–100% 
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 EtOAc in hexanes) to afford 215 (0.566 g, 43%) as a faintly yellow oil.  Rf = 0.80 (75% EtOAc 
in hexanes). 
Method B: To a stirring solution of 3-methoxyphenylmagnesium bromide (30.0 mL, 1M 
in THF) in THF (30 mL) at 0 °C was added slowly, in portions, allyl bromide.  The resulting 
solution was stirred at 25 °C for 24 h before being partitioned between Et2O (20 mL) and sat. aq. 
NH4Cl (20 mL).  The layers were separated and the aqueous layer was extracted with Et2O (2 x 
20 mL).  The combined organic layers were washed with brine (20 mL), dried over MgSO4, 
filtered and concentrated in vacuo.  The residue was purified by chromatography on SiO2 (0–
100% EtOAc in hexanes) to afford 215 (4.29 g, 97%) as a faintly yellow oil.  Rf = 0.53 (10% 
EtOAc in hexanes); 1H NMR (600 MHz, CDCl3) δ 6.86 (d, J = 8.4 Hz, 1H), 6.70 (m, 2H), 5.99 
(ddt, J = 7.2, 10.2, 17.4 Hz, 1H), 5.48 (s, 1H), 5.09 (dd, J = 1.8, 17.4 Hz, 1H), 5.06 (dd, J = 1.8, 
10.2 Hz, 1H), 3.88 (s, 3H), 3.33 (d, J = 6.6 Hz, 2H); 13C NMR (150 MHz, CDCl3) δ 146.56, 
144.03, 137.96, 132.06, 121.31, 115.67, 114.36, 111.21, 55.99, 40.04. 
 
 
 
 
Preparation of 219.  
Method A: Magnesium turnings (0.130 g, 5.35 mmol) were stirred in a solution of THF 
(13 mL) in a dried flask filled with N2 for 10 minutes.  Then, 3-bromoanisole (1.00 g, 5.35 
mmol) was added in small portions via syringe, followed by I2 (0.046 g, 0.182 mmol).  The 
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 solution was brought to reflux (~70 °C), and stirred for 16 h.  At this point, the oil bath was 
removed, and the solution was allowed to cool to r.t. before an ice bath was applied.  Once the 
reaction solution was 0 °C, the reflux condenser was removed.  A solution of (S)-(+)-
epichlorohydrin (0.33 mL, 4.3 mmol) in THF (8.5 mL) was added dropwise to the stirring 
mixture.  The ice bath was removed, and stirring continued for an additional 2 h.  The reaction 
was quenched with 1M HCl (5 mL) and extracted with Et2O (3 x 8 mL), and then the combined 
organic layers were dried over Na2SO4, filtered, and concentrated in vacuo.  The crude material 
(1.32 g) was isolated as a yellow oil, and used immediately in the subsequent reaction. 
Method B:  A solution of 3-methoxyphenylmagnesium bromide (24.0 mL, 1M in THF) 
was added dropwise to a stirred mixture of (S)-(+)-epichlorohydrin (1.56 mL, 20.0 mmol) and 
CuCN (0.179 g, 2.00 mmol) in THF (22 mL) that had been pre-cooled to -78 °C.  The resulting 
solution was allowed to warm to -20 °C over a period of 3 h.  The reaction mixture was poured 
into a solution of sat. aq. NH4Cl (25 mL) and Et2O (25 mL) and stirred vigorously.  The layers 
were separated, and the aqueous layer was extracted with additional Et2O (3 x 50 mL).  The 
combined organic layers were washed with brine (50 mL), then dried over MgSO4, filtered, and 
concentrated in vacuo.  The faintly yellow residue was purified by chromatography on SiO2 (0–
100% EtOAc in hexanes) to afford 219 (3.967 g, 99%) as a colorless oil.  Rf = 0.27 (20% EtOAc 
in hexanes); 1H NMR (600 MHz, CDCl3) δ; 7.28 (t, J = 7.8 Hz, 1H), 6.85 (m, 3H), 4.10 (m, 1H), 
3.83 (s, 3H), 3.66 (dd, J = 4.2, 11.4 Hz, 1H), 3.52 (dd, J = 6.0, 11.4 Hz, 1H), 2.88 (d, J = 6.6 Hz, 
2H), 2.21 (d, J = 6.6 Hz), 2.31 (br s, 1H); 13C NMR (150 MHz, CDCl3) δ 159.86, 138.63, 
129.83, 121.73, 115.16, 112.19, 72.24, 55.29, 49.28, 40.69; m/z (APCI) [M - Cl]+ 165. 
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Preparation of 220. Crushed NaOH pellets (0.548 g, 13.7 mmol) were added to a flask 
containing 219 (0.500 g, 2.492 mmol) in Et2O (2.8 mL).  This sample was stirred for 20 h at 25 
°C, whereupon H2O (3 mL) was added.   The aqueous layer was extracted with Et2O (3 x 4 mL), 
then the combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo.  
The residue was purified by chromatography on SiO2 (5–100% EtOAc in hexanes) to afford 220 
(0.304 g, 74%) as a colorless oil.  Rf = 0.60 (20% EtOAc in hexanes); 1H NMR (600 MHz, 
CDCl3) δ 7.25 (t, J = 7.8 Hz, 1H), 6.85 (d, J = 7.2 Hz, 1H), 6.81 (m, 2H), 3.81 (s, 3H), 3.17 (m, 
1H), 2.92 (dd, J = 15.0, 5.4 Hz, 1H), 2.81 (t, J = 4.2 Hz, 1H), 2.81 (dd, J = 15, 5.4 Hz, 1H), 2.57 
(dd, J = 4.8, 3.0); 13C NMR (150 MHz, CDCl3) δ 159.85, 138.90, 129.66, 121.47, 114.89, 
112.11, 55.33, 52.54, 47.07, 38.98; m/z (APCI) [M + 1]+ 165. 
 
 
 
 
Preparation of 206. Epoxide 220 (0.104 g, 0.633 mmol) and a solution of NH4OH (25% in H2O, 
4.2 mL) were stirred in EtOH (4 mL) at 25 °C for 22 h.  The solution was then heated to 70 °C, 
and stirred for an additional 23 h, at which point the solution was concentrated to ~1 mL.  The 
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 solution was extracted with CH2Cl2 (3 x 2 mL), and the combined organic layers were dried over 
Na2SO4, filtered, and concentrated in vacuo to afford 206 (0.101 g, 88%). 1H NMR (600 MHz, 
CDCl3) δ 7.24 (m, 1H), 6.82 (d, J = 7.8 Hz, 1H), 6.78 (m, 2H), 3.80 (s, 3H), 3.78 (m, 1H), 2.87 
(br s, 1H), 2.74 (dd, J = 7.2, 1.8 Hz), 2.61 (br s, 1H), 1.27 (t, J = 7.2 Hz, 1H). 
 
 
 
 
Preparation of 218. To a stirring solution of alkene 215 (4.01 g, 27.0 mmol) in THF (108 mL) 
at 0oC was added dropwise 9-borabicyclo[3.3.1]nonane (85.0 mL, 42.5 mmol).  The resulting 
solution was stirred at r.t. for 4 h.  The solution was cooled to 0oC, then the following were 
sequentially added: a solution of EtOH and THF (35 mL each), pH 7 phosphate buffer (70 mL), 
and H2O2 (30% in H2O, 70 mL).  This mixture was stirred at 0oC for 30 min and at r.t. for 10 h.  
To quench the reaction, diethyl ether (75 mL) and 20% Na2S2O3 (110 mL) were added.  The 
aqueous layer was extracted with CH2Cl2 (2 x 50 mL), then the combined organic layers were 
washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo.  The residue was 
purified by chromatography on SiO2 (0–100% EtOAc in hexanes) to afford 218 (3.01 g, 67%) as 
a colorless oil. Rf = 0.35 (50 % EtOAc in hexanes); 1H NMR (600 MHz, CDCl3) δ 7.22 (t, J = 
7.8 Hz, 1H), 6.81 (d, J = 7.2 Hz, 1H), 6.75 (m, 2H), 3.80 (s, 3H), 3.69 (t, J = 6.0 Hz, 1H), 2.70 
(t, J = 7.8 Hz, 1H), 1.92 (tt, J = 6.6, 7.8 Hz, 1H), 1.66 (br s, 1H); 13C NMR (150 MHz, CDCl3) δ 
 85 
 159.70, 143.59, 129.48, 120.94, 114.28, 111.17, 62.34, 55.24, 34.20, 32.23; m/z (ESI) [M + 1]+ 
167.1, [M - H2O]+ 149.2.  
 
 
 
 
Preparation of 207. TEMPO (0.036 g, 0.23 mmol) and PhI(OAc)2 (0.806 g, 2.50 mmol) were 
added to a stirring solution of 218 (0.189 g, 1.14 mmol) in MeCN (6 mL) and H2O (6 mL), and 
the reaction solution was stirred at 25 °C for 24 h.  The reaction was then quenched by the 
addition of Na2S2O3 (10% in H2O, 10 mL).  The aq layer was extracted with EtOAc (3 x 10 mL).  
The combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuo.  The residue was purified by chromatography on SiO2 (0–100% EtOAc in 
hexanes) to afford 207 (0.196 g, 96%) as a yellow oil.  Rf = 0.58 (50% EtOAc in hexanes); 1H 
NMR (600 MHz, CDCl3) δ 7.25 (t, J = 7.8 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 201.75, 
159.94, 142.09, 129.76, 120.75, 114.30, 111.66, 55.31, 45.34, 28.30; IR (neat) 3253 (broad), 
2937, 1720, 1600, 1583, 1257, 1151, 1036, 778, 694 cm-1; m/z (ESI) [M + 1]+ 181.2, [M + Na]+ 
203.9. 
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Preparation of 219. Triphenylphosphine (0.710 g, 2.71 mmol) and I2 (0.687 g, 2.71 mmol) were 
dissolved in CH2Cl2 at 0 °C and stirred for 10 min.  Imidazole (0.307 g, 4.51 mmol) was then 
added, and the solution was stirred for another 10 min.  Then alcohol 218 in 1 mL CH2Cl2 was 
added dropwise.  The ice bath was removed and stirring continued at r.t. for 3 h.  At that time, 
sat. aq. Na2S2O3 (20 mL) was added.  The aqueous layer was extracted with CH2Cl2 (3 x 10 
mL); the combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered 
and concentrated in vacuo.  The residue was purified by chromatography on SiO2 (0–100% 
EtOAc in hexanes) to afford 219 (0.427 g, 86%) as an orange oil.  Rf = 0.73 (50% EtOAc in 
hexanes); 1H NMR (600 MHz, CDCl3) δ 7.23 (t, J = 7.8 Hz, 1H), 6.80 (m, 3H), 3.81 (s, 3H), 
3.18 (t, J = 7.2 Hz, 2H), 2.72 (t, J = 7.2 Hz, 2H), 2.15 (pentet, J = 7.2 Hz, 2H); 13C NMR (150 
MHz, CDCl3) δ 159.69, 142.05, 129.51, 120.97, 114.35, 111.41, 55.20, 36.24, 34.77, 6.58.  
 
 
 
 
Preparation of 220. Methanesulfonyl chloride (0.21 mL, 2.7 mmol) and NEt3 (0.50 mL, 3.6 
mmol) were sequentially added to a stirring solution of 218 (0.300 g, 1.81 mmol) in CH2Cl2 (18 
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 mL).  The reaction was stirred at r.t. for 3 h before it was quenched by the addition of sat. aq. 
NaHCO3 (20 mL).  The aqueous layer of the resulting solution was extracted with CH2Cl2 (3 x 
20 mL), the organic layer was washed with brine (20 mL), dried over Na2SO4, filtered, and 
concentrated.  The crude orange oil (220) was used in the next reaction without any further 
purification.  Rf = 0.44 (50% EtOAc in hexanes); 1H NMR (600 MHz, CDCl3) δ7.23 (t, J = 7.2 
Hz, 1H), 6.79 (m, 3H), 4.24 (t, 6.0 Hz, 2H), 3.80 (s, 3H), 3.00 (s, 3H), 2.74 (t, J = 7.2 Hz, 2H), 
2.10 (pentet, J = 6.6 Hz, 2H); 13C NMR (150 MHz, CDCl3) δ 159.92, 142.02, 129.72, 120.93, 
114.41, 111.68, 69.24, 55.31, 37.49, 31.69, 30.66; m/z (ESI) [M + Na]+ 267.1. 
 
 
 
 
Preparation of 221 
Method A: To a solution of iodide 219 (0.420 g, 1.52 mmol) in DMF (1.5 mL) was 
added NaN3 (0.198 g, 3.04 mmol).  This mixture was then stirred at 25 °C for 1 h and then at 40 
°C for an additional 20 h.  The reaction was then quenched by the addition of sat. aq. NaHCO3 
(20 mL) and sat. aq. Na2S2O3 (20 mL).  The aqueous layer was extracted with CH2Cl2 (5 x 15 
mL), the combined organic layers were washed with H2O (3 x 10 mL) and brine (10 mL), then 
dried over Na2SO4, filtered and concentrated in vacuo.  The residue was purified by 
chromatography on SiO2 (0–100% EtOAc in hexanes) to afford 221 (0.291 g, 75%) as a 
colorless oil. 
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 Method B: To a solution of mesylate 220 (0.441 g, 1.81 mmol) in DMF (1.8 mL) was 
added NaN3 (0.469 g, 7.22 mmol).  This mixture was then stirred at 25 °C for 1 h and then at 40 
°C for an additional 24 h.  The reaction was then quenched by the addition of sat. aq. NaHCO3 
(20 mL) and sat. aq. Na2S2O3 (20 mL).  The aqueous layer was extracted with CH2Cl2 (5 x 15 
mL), the combined organic layers were washed with H2O (3 x 10 mL) and brine (10 mL), then 
dried over Na2SO4, filtered and concentrated in vacuo.  The residue was purified by 
chromatography on SiO2 (0–100% EtOAc in hexanes) to afford 221 (0.345 g, 76%) as a 
colorless oil.  Rf = 0.67 (50% EtOAc in hexanes); 1H NMR (600 MHz, CDCl3) δ 7.23 (t, J = 7.8 
Hz, 1H), 6.79 (m, 2H), 3.81 (s, 3H), 3.30 (t, J = 6.6 Hz, 2H), 2.70 (t, J = 7.2 Hz, 2H), 1.94 
(pentet, J = 7.2 Hz). 
 
 
 
 
Preparation of 208. H2O (0.16 mL) and then triphenylphosphine (1.17 g, 4.45 mmol) were 
added to a solution of azide 221 (.340 g, 1.78 mmol) in THF (18 mL) at 25 °C.  The mixture was 
heated to 40 °C, then stirred 20 h.  An additional 1.6 mL of H2O was added, and the mixture was 
stirred for another 24 h.  After concentrating the solution, it was dissolved in CH2Cl2 (10 mL) 
and washed with 1 M HCl (3 x 10 mL), allowing for unreacted starting material to be collected 
(0.105 g).  The aqueous layer was extracted with EtOAc (3 x 10 mL), and then 3 M NaOH was 
added to the aqueous layer until the pH reached 10.  The aqueous layer was then extracted with 
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 CH2Cl2 (3 x 10 mL).  The combined organic layers were dried over Na2SO4, filtered and 
concentrated in vacuo.  The residue was purified by chromatography on SiO2 (0–100% EtOAc in 
hexanes) to afford 208 (0.11 g, 37%, 94% BRSM) as a faintly yellow oil.  Rf = 0.18 (50% EtOAc 
in hexanes); 1H NMR (600 MHz, CDCl3) δ 7.20 (t, J = 7.2 Hz, 1H), 6.78 (m, 2H), 3.79 (s, 3H), 
2.74 (br t, J = 6.0 Hz, 2H), 2.64 (t, J = 7.2 Hz, 2H), 1.96 (br s, 2H), 1.81 (pentet, J = 7.2 Hz, 2H); 
13C NMR (150 MHz, CDCl3) δ 159.76, 143.83, 129.44, 120.93, 114.29, 111.16, 55.26, 41.79, 
35.19, 33.41; m/z (ESI) [M + 1]+ 166.2, [M – NH3]+ 149.1, [M – CH2NH3]+ 136.1. 
 
 
 
 
Preparation of 223. To a solution of 7-methylcoumarin (4.00 g, 25.0 mmol) in CCl4 (125 mL), 
N-bromosuccinimide (4.57 g, 25.7 mmol) and benzoyl peroxide (0.363 g, 1.50 mmol) were 
sequentially added.  The reaction solution was heated to reflux, and stirred 24 h.  When the 
reaction had finished, the solution was concentrated in vacuo, and purified by chromatography 
on SiO2 (10–100% EtOAc in hexanes) to afford 223 (4.33 g, 73%) as a pale yellow solid.  Rf = 
0.19 (25% EtOAc in hexanes); 1H NMR (600 MHz, CDCl3) δ 7.70 (d, J = 9.6 Hz, 1H), 7.47 (d, J 
= 7.8 Hz, 1H), 7.35 (s, 1H), 7.32 (dd, J = 7.8, 1.8 Hz, 1H), 6.44 (d, J = 9.6 Hz, 1H), 4.52 (s, 2H); 
13C NMR (150 MHz, CDCl3) δ 160.65, 154.21, 142.94, 142.12, 128.43, 125.34, 118.85, 117.39, 
117.29, 31.95; m/z (APCI) [M + 1]+ 239, [M + 3]+ 241. 
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Preparation of 209. To a solution of crude bromide 223 (4.330 g, 18.11 mmol) in DMSO (50 
mL) was added sodium nitrite (5.17 g, 74.9 mmol) and acetic acid (13.6 mL, 237 mmol).  The 
mixture was heated to 100 °C and stirred for 4 h.  Once the mixture cooled to 25 °C, a 37% HCl 
solution was added dropwise until the pH reached 1.5.  The solution was extracted with Et2O (6 
x 80 mL); the combined organic layers were then washed with H2O (300 mL), dried over 
Na2SO4, filtered, and concentrated in vacuo to afford 209 (2.80 g, 81%) as a pale yellow solid.  
NMR shows slight contamination with succinimide.  1H NMR (600 MHz, DMSO-d6) δ 8.11 (d, J 
= 9.6 Hz, 1H), 7.84 (dd, J = 7.8, 1.2 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.77 (s, 1H), 6.59 (d, J = 
9.6 Hz, 1H) ; 13C NMR (150 MHz, DMSO-d6) δ 166.22, 159.65, 153.20, 143.46, 133.59, 128.87, 
124.89, 122.18, 118.35, 116.88; m/z (APCI) [M + 1]+ 191. 
 
 
 
 
Preparation of 224.  To a solution of sodium azide (0.139 g, 2.14 mmol) in DMSO (4 mL) was 
sequentially added bromide 223 and then tetraethylammonium bromide (2 mg, 10 μmol).  The 
solution was then stirred 20 h at r.t.  At this point, sodium iodide (0.087 g, 0.58 mmol) was 
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 added and the reaction was stirred for an additional 24 h.  Workup was carried out through the 
addition of water (10 mL).  The aqueous layer was extracted with CH2Cl2 (3 x 10 mL), the 
combined organic layers were then washed with water (2 x 10 mL) and brine (10 mL), dried over 
Na2SO4, filtered and concentrated in vacuo.  The crude orange solid (224) was used in the 
following step without further purification.  1H NMR (600 MHz, DMSO-d6) δ 7.88 (d, J = 9.0 
Hz, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.45 (m, 2H), 6.60 (d, J = 9.6 Hz, 1H), 4.61 (s, 2H); 13C NMR 
(150 MHz, DMSO-d6) δ 160.70, 154.28, 143.12, 140.02, 128.49, 124.06, 118.65, 117.09, 
116.32, 54.15; m/z (APCI) [M + 1]+ 202. 
 
 
 
 
Preparation of 210.  
Method A: Bromide 223 (0.200 g, 0.837 mmol) in CHCl3 (4 mL) was added to a stirring 
solution of hexamethylenetetramine (0.164 g, 1.17 mmol) in EtOH (6 mL).  The resulting 
solution was stirred at 25 °C for 24 h, heated at 80 °C for 4 h, and then stirred for an additional 
12 h at 25 °C.  The precipitate was filtered and washed with cold EtOH.  The solid residue was 
collected and diluted with additional EtOH (7.4 mL), then 12 N HCl (0.27 mL) was added 
slowly, and the biphasic solution was stirred at 55 °C for 30 min.  The mixture was cooled to 
room temperature and concentrated overnight.  The solid residue was diluted with hexanes (3 
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 mL) and stirred for 15 min.  Filtration, followed by two days under vacuum furnished 210 as an 
orange solid (0.146 g, 99%).   
Method B: Water (0.16 mL) and then triphenylphosphine (1.17 g, 4.47 mmol) were 
added to a solution of azide 224 (0.360 g, 1.79 mmol) in THF (18 mL) at 25 °C.  The mixture 
was heated to 40 °C, then stirred 20 h.  An additional 1.6 mL of H2O was added, and the mixture 
was stirred for another 24 h.  After concentrating the solution, it was dissolved in CH2Cl2 (10 
mL) and washed with 1 M HCl (3 x 10 mL), allowing for unreacted starting material to be 
collected (0.304 g).  The aqueous layer was extracted with EtOAc (3 x 10 mL), and then 3 M 
NaOH was added to the aqueous layer until the pH reached 10.  The aqueous layer was then 
extracted with CH2Cl2 (3 x 10 mL).  The combined organic layers were dried over Na2SO4, 
filtered and concentrated in vacuo.  The residue was purified by chromatography on SiO2 (0–
100% EtOAc in hexanes) to afford 210 (0.035 g, 11%, 72% BRSM).  NMR was initially taken 
with CDCl3 as the solvent, and the sample was concentrated before taking an additional NMR 
using DMSO-d6.  The reported NMR spectra show CDCl3 contamination. 1H NMR (600 MHz, 
DMSO-d6) δ 8.61 (br s, 2H), 8.10 (d, J = 9.0 Hz, 1H), 7.77 (d, J = 7.8 Hz), 7.59 (s, 1H), 7.48 
(dd, J = 7.8, 1.2 Hz, 1H),  6.54 (d, J = 9.6 Hz, 1H), 4.15 (br s, 2H); 13C NMR (150 MHz, DMSO-
d6) δ 159.83, 153.30, 143.92, 138.38, 128.58, 125.03, 118.53, 116.61, 116.57, 41.63; m/z (ESI) 
[M + H]+ 176.0, [M – NH3]+ 159.0. 
 
 
 
 
 93 
 Preparation of 226. Ethyl glycolate (1.03 mL, 10.8 mmol) was diluted into a solution of 
anhydrous CH2Cl2 (5 mL) and cyclohexanes (10 mL), and then cooled to 0°C.  To this solution 
was added dropwise para-methoxy benzyl trichloroacetimidate (3.67 mL, 13.0 mmol) in CH2Cl2 
(1.00 mL), followed by pyridinium para-toluenesulfonate (0.272 g, 1.08 mmol) in one portion.  
The mixture was warmed to 25°C after removal of the ice bath and stirred for 20 h, after which it 
was filtered through a plug of silica (3 mL) that was subsequently flushed with 20% EtOAc in 
hexanes solution (15 mL).  The filtrate was washed with NaHCO3 (10 mL), dried over Na2SO4, 
filtered, and concentrated in vacuo.  The residue was purified by chromatography on SiO2 (5–
100% EtOAc in hexanes) to afford 226 (2.43 g, 89%) as a colorless oil. Rf = 0.30 (25% EtOAc in 
hexanes); 1H NMR (600 MHz, CDCl3) δ 7.30 (d, J = 8.4 Hz, 2H), 6.89 (d, J = 8.4 Hz, 2H), 4.57 
(s, 2H), 4.21 (q, J = 7.2 Hz, 2H), 4.06 (s, 2H), 3.81 (s, 3H), 1.30 (t, J = 6.6, 3H); 13C NMR (150 
MHz, CDCl3) δ 170.60, 159.63, 129.94, 129.30, 114.01, 73.093, 67.04, 60.99, 55.42, 14.35. 
 
 
 
 
Preparation of 227. To a stirring solution of 226 (0.280 g, 1.25 mmol) in anhydrous CH2Cl2 (6 
mL) under N2 at -15 °C was added dropwise diisobutylaluminum hydride (1.87 mL, 1M in 
toluene, 1.87 mmol) and stirred 1.5 h.  The reaction solution was quenched with 0.20 mL 
methanol, saturated aqueous sodium potassium tartrate (8 mL) was added, and the solution was 
allowed to warm to 25 °C while stirring vigorously.  The organic layer was separated and the 
aqueous layer was extracted with CH2Cl2 (3 x 8 mL).  The combined organic layers were washed 
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 with brine (10 mL), dried over Na2SO4, filtered, and concentrated in vacuo.  The residue was 
purified by chromatography on SiO2 (0–100% EtOAc in hexanes) to afford 227 (0.170 g, 76%) 
as a colorless oil.  Rf = 0.45 (50% EtOAc in hexanes); 1H NMR (600 MHz, CDCl3) δ 9.71 (s, 
1H), 7.30 (d, J = 8.4 Hz, 2H), 6.91 (d, J = 8.4 Hz, 2H), 4.57 (s, 2H), 4.07 (s, 2H), 3.81 (s, 3H); 
13C NMR (150 MHz, CDCl3) δ 200.80, 159.77, 129.93, 128.98, 114.13, 75.15, 73.49, 55.44. 
 
 
 
 
Preparation of 228. A flask fitted with a reflux condenser was charged with crushed and oven-
dried 4Å molecular sieves (3.43 g), a 0.10 M solution of (S)-1,1’-bi-2-naphthol (0.508 g, 1.78 
mmol) in CH2Cl2 (17.8 mL), a 1.0 M solution of titanium isopropoxide (0.27 mL, 0.888 mmol) 
in CH2Cl2 (0.90 mL), and a 1.0 M solution of trifluoroacetic acid (4.8 µL, 0.0622 mmol) in 
CH2Cl2 (60 µL).  The reaction mixture was stirred and heated at reflux for 1 h and then allowed 
to cool to 25 °C.  A 3.0 M solution of aldehyde 227 (1.60 g, 8.88 mmol) in CH2Cl2 (3.0 mL) was 
added, using an additional 0.1 mL CH2Cl2 to transfer the remaining aldehyde residue to the 
reaction flask.  The mixture was stirred for 30 min before cooling to -78 °C.  
Allyltributylstannane (3.6 mL, 11.543 mmol) was added dropwise at this temperature to the 
mixture, and stirred an additional 10 minutes at -78 °C before being transferred to a -20 °C 
freezer, where it was manually agitated daily.  After 6 days, the reaction mixture was filtered 
over a pad of Celite (4 mL), which was flushed with CH2Cl2 (10 mL).  The filtrate was then 
quenched with NaHCO3 (10 mL) and stirred for 1 h before separating the layers.  The aqueous 
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 layer was extracted with CH2Cl2 (2 x 10 mL), the combined organic layers were washed with 
brine (10 mL), dried over Na2SO4, filtered, and concentrated in vacuo to give the crude product 
as a red-orange oil.  The residue was purified by chromatography on SiO2 (0–100% EtOAc in 
hexanes) to afford 228 (1.78 g, 90%) as a colorless oil.  Rf = 0.53 (50% EtOAc in hexanes); 1H 
NMR (600 MHz, CDCl3) δ 7.27 (d, J = 8.4 Hz, 2 H), 6.90 (d, J = 8.4 Hz, 2H), 5.86 (ddt, J = 
10.2, 16.8, 7.2 Hz, 1H), 5.13 (dd, J = 3.3, 16.8 Hz, 1H), 5.10 (dd, J = 3.3, 10.2 Hz, 1H), 4.49 (s, 
2H), 3.88 (m, 1H), 3.81 (s, 3H), 3.50 (dd, J = 3.0, 9.6 Hz, 1H), 3.36 (dd, J = 7.2, 9.6 Hz, 1H), 
2.30 (d, J = 3.6 Hz, 1 H), 2.27 (t, J = 7.2 Hz, 2H); 13C NMR (150 MHz, CDCl3) δ 159.44, 
134.39, 130.17, 129.53, 117.79, 113.98, 73.73, 73.17, 55.41, 38.03. 
 
 
 
 
Preparation of 229. To a stirring solution of 228 (1.75 g, 7.87 mmol) and imidazole (1.07 g, 
15.7 mmol) in CH2Cl2 (78 mL) was cooled to 0 °C and then tert-butyldimethylsilyl chloride 
(1.78 g, 11.8 mmol) was quickly added.  The reaction solution was stirred at 25 °C for 12 h, and 
was then diluted with diethyl ether (100 mL), washed with H2O (2 x 100 mL) and brine (100 
mL), dried over MgSO4, filtered, and concentrated in vacuo.  The residue was purified by 
chromatography on SiO2 (5–100% EtOAc in hexanes) to afford 229 (2.20 g, 83%) as a colorless 
oil.  Rf = 0.60 (25% EtOAc in hexanes); 1H NMR (600 MHz, CDCl3) δ 7.26 (d, J = 8.4 Hz, 2H), 
6.88 (d, J = 8.4 Hz, 2H), 5.85 (ddt, J = 10.2, 16.8, 7.2 Hz, 1H), 5.07 (d, J = 16.8 Hz, 1H), 5.04 
(d, J = 10.2 Hz, 1H), 4.45 (d, J = 0.06 Hz, 2H), 3.88 (m, 1H), 3.81 (s, 3H), 3.37 (dd, J = 1.8, 5.4 
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 Hz, 2H), 2.36 (ddd, J = 6.6, 6.6, 13.2 Hz, 1H), 2.23 (ddd, J = 6.6, 6.6, 13.2 Hz, 1H), 0.88 (s, 9H), 
0.05 (s, 3H), 0.04 (s, 3H); 13C NMR (150 MHz, CDCl3) δ159.23, 135.16, 130.71, 129.35, 
117.11, 113.84, 74.10, 73.10, 71.34, 55.42, 39.54, 26.01, 18.33, –4.31, –4.56. 
 
 
 
 
Preparation of 230. To a stirred solution of 229 (0.073 g, 0.22 mmol) in acetone (0.67 mL) and 
H2O (67 µL) was added 2,6-lutidine (50.3 µL, 0.434 mmol), 4-methylmorpholine N-oxide (0.038 
g, 0.326 mmol), and osmium tetroxide (1.1 mg, 4.34 µmol).  This solution was stirred 14 h, then 
(diacetoxyiodo)benzene (0.105 g, 0.326 mmol) was added, and the mixture was stirred an 
additional 3 h.  The reaction mixture was quenched with saturated aqueous Na2S2O3 (7 mL), the 
aqueous layer was extracted with EtOAc, the combined organic layers were washed with 
saturated aqueous CuSO4 (2 x 14 mL), dried over Na2SO4, filtered, and concentrated in vacuo.  
The residue was purified by chromatography on SiO2 (0–100% EtOAc in hexanes) to afford 230 
(0.065 g, 89%) as a colorless oil.  Rf = 0.50 (25% EtOAc in hexanes); 1H NMR (600 MHz, 
CDCl3) δ 9.79 (s, 1H), 7.24 (d, J = 9.0 Hz, 2H), 6.88 (d, J = 8.4 Hz, 2H), 4.45 (d, J = 1.8 Hz, 
2H), 4.36 (m, 1H), 3.81 (s, 3H), 3.49 (dd, J = 5.4, 9.6 Hz, 1H), 3.37 (dd, J = 6.6, 9.6 Hz, 1H), 
2.66 (ddd, J = 2.4, 5.4, 15.6 Hz, 1H), 2.58 (ddd, J = 2.4, 6.6, 15.6 Hz, 1H), 0.86 (s, 9H), 0.06 (s, 
3H), 0.06 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 201.70, 159.39, 130.17, 129.44, 113.93, 73.82, 
73.20, 67.48, 55.42, 49.12, 25.87, 18.16, –4.32, –4.83. 
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Preparation of 231. To a solution of potassium tert-butoxide (0.020 g, 0.18 mmol) and trans-2-
butene (0.022 mL, 0.25 mmol), stirring at -78 °C in THF (0.17 mL), was added dropwise n-BuLi 
(0.106 mL, 2.4 M in hexanes, 0.170 mmol).  The resulting mixture was stirred for 20 min at -45 
°C, before being cooled once again to -78 °C.  A solution of (+)-β-methoxy 
diisopinocampheylborane (0.063 g, 0.201 mmol) in THF (100 µL) was added, and stirring 
continued at this temperature for 35 min.  To this mixture was quickly added BF3•OEt2 and then 
a solution of aldehyde 230 (0.040 g, 0.118 mmol) in THF (0.05 mL).  The reaction was quenched 
after stirring for 4 h by the addition of 3N NaOH (0.11 mL) and then H2O2 (30% in H2O, 0.11 
mL).  The cooling bath was removed, and the reaction mixture was then stirred 12 h at 25 °C.  
After dilution with EtOAc (2 mL) and brine (2 mL), the aqueous layers were washed with 
EtOAc (3 x 2 mL), the combined organic layers were dried over MgSO4, filtered, and 
concentrated in vacuo.  The residue was purified by careful chromatography on SiO2 (2.5–100% 
EtOAc in hexanes) to afford 231 (0.020 g, 42%) as a colorless oil.  Rf = 0.53 (25% EtOAc in 
hexanes); 1H NMR (600 MHz, CDCl3) δ 7.25 (d, J = 8.4, 2H), 6.88 (d, J = 8.4, 2H), 5.83 (ddd, J 
= 16.8, 10.8, 7.8 Hz, 1H), 5.08 (dd, J = 10.2, 1.2 Hz, 1H), 5.08 (dd J = 16.8, 1.2 Hz, 1H), 4.49 (d, 
J = 11.4 Hz, 1H), 4.14 (ddd, J = 10.8, 6.0, 5.4 Hz, 1H), 3.81 (s, 3H), 3.72 (m, 1H), 3.47 (dd, J = 
9.6, 5.4 Hz, 1H), 3.06 (br s, 1H), 2.21 (m, 1H), 1.69 (ddd, J = 14.4, 5.4, 1.8 Hz, 1H), 1.63 (ddd, J 
= 14.4, 10.8, 4.2 Hz, 1H), 1.03 (d, J = 7.2, 3H), 0.88 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H); 13C NMR 
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 (150 MHz, CDCl3) δ 159.36, 140.83, 130.31, 129.47, 115.42, 113.92, 73.39, 73.10, 71.53, 70.35, 
55.45, 44.34, 37.78, 25.98, 18.22, 15.94, –4.41, –4.90. 
 
 
 
Preparation of 232. To a stirred solution of alkene 231 (15 mg, 0.038 mmol) in CH2Cl2 (0.5 
mL) was added 4-(dimethylamino)pyridine (0.3 mg, 0.003 mmol), and the resulting solution was 
then cooled from 25 °C to -78 °C.  Triethylamine (13.2 µL) was added and then acryloyl 
chloride (6.2 µL) was added.  The solution was diluted with CH2Cl2 after 2 h, quenched with the 
addition of brine, and warmed to 25 °C.  The aqueous layer was extracted with CH2Cl2, the 
combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to afford a 
10.5:1 mixture of 231 to 232 (21 mg mixture, <8%) as a yellow oil.  Rf = 0.47 (25% EtOAc in 
hexanes. m/z (APCI) [M +1]+ 449. 
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 APPENDIX A 
ANTIPROLIFERATIVE ACTIVITY OF DISCODERMOLIDE ANALOGUES 
This appendix has been included to accompany the SAR studies discussed in Section 1.4 of this 
document.  It begins with Table 2, which summarizes the notable features of each of the cell 
lines involved in these SAR studies.  The remaining tables include all antiproliferative data for 
these analogues in each of the cell lines that were assayed.  Tables are organized by the figure in 
which they appeared in Section 1.4.  Due to the range of measured IC50 values for the parent 
compound in each study, the data is presented in two forms.   
1) Antiproliferative data is presented as a ratio of [activity of analogue]/[activity of 
parent, as measured in that particular study].  A heat map was generated to color 
code the individual analogues according to their activity when compared to the 
parent; analogues that perform as well or better than the parent are shaded green, 
and analogues that perform significantly worse than the parent are shaded red. 
2) Unprocessed data is presented, showing the antiproliferative activity of both the 
analogue and the parent for each figure without further calculations performed. 
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Table 2. Characterization of cell lines used in discodermolide SAR studies. 
 
 
Cell Line Notes 
1A9 Human ovarian carcinoma 
1A9-PTX22 Paclitaxel-resistant human ovarian carcinoma; contains β-tubulin mutation A364T 
2008 Human ovarian cystadenocarcinoma 
A549 Human non-small cell lung adenocarcinoma 
CCRF-CEM Human acute lymphocytic leukemia 
HCT116 Human colorectal carcinoma 
MCF-7 Human breast ductal carcinoma 
MDA-MB231 Human breast carcinoma 
MG63 Human osteosarcoma 
MIP101 Undifferentiated human colon carcinoma 
NCI/ADR Multidrug-resistant OVCAR-8 human ovarian carcinoma (originally named MCF-7/ADR); expresses high levels of MDR1 and P-glycoprotein)  
P388 Murine lymphocytic leukemia 
PANC-1 Human pancreatic ductal carcinoma 
PC-3 Human prostate adenocarcinoma 
SKOV-3 Human ovarian adenocarcinoma 
VERO Normal (non-cancerous) kidney epithelial cell line of the African green monkey 
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 Table 3. IC50 values for carbamate fragment analogues, presented as a ratio of analogue to parent. 
 
Table 4. IC50 values for linker fragment analogues, presented as a ratio of analogue to parent. 
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 Table 5. IC50 values for lactone fragment analogues, presented as a ratio of analogue to parent. 
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 Table 6. IC50 values for analogues with multiple regions of alteration, presented as a ratio of analogue to parent. 
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 Table 7. Analogues with measured GI50 values, rather than IC50 values, presented as a ratio of analogue to parent. 
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 Table 8. IC50 values (nM) for discodermolide (left) and carbamate fragment analogues (right). 
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 Table 9. IC50 values (nM) for discodermolide (left) and linker fragment analogues (right). 
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 Table 10. IC50 values (nM) for discodermolide (left) and lactone fragment analogues (right).  
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 Table 11. IC50 values (nM) for discodermolide (left) and analogues with multiple modifications (right). 
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 Table 12. GI50 values (nM) for discodermolide (left) and analogues with multiple modifications (right). 
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 APPENDIX B 
EXPERIMENTAL SPECTRA 
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